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Subtle changes in the neural retina can be detected much earlier than retinal 
vasculopathy in diabetic retinopathy. In mice fed a high fat diet, we have found early and 
progressive decline in visual acuity, as measured by optokinetic tracking, even before 
significant weight gain and hyperglycemia. Fundus examination was normal and 
fluorescein angiography showed normal retinal vasculature. The only major histologic 
findings were swollen mitochondria, edema and degenerative changes in the retinal 
pigment epithelium (RPE). Outer retinal ischemia and inflammation are supported by 
elevated VEGF, TNFa, MCP-1, and choroidal neovascular tufts. Treatment with a 
mitochondria-targeted tetrapeptide (SS-31/MTP-131) reversed visual decline without 
reducing blood glucose, body weight or insulin resistance. SS-31 is known to target 
cardiolipin and promote electron transfer and ATP synthesis. SS-31 preserved 
mitochondrial morphology and integrity of the RPE, reduced inflammatory markers, and 
prevented choroidal neovascularization. These results demonstrate a causal relationship 
between RPE mitochondrial energy failure and loss of visual acuity in early metabolic 
syndrome, and support a bioenergetics-based approach for preventing diabetic 
complications. A topical formulation of SS-31 (OcuviaTM) is in Phase 2 clinical trial for 
diabetic macula edema and non-proliferative age-related macular degeneration. 	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INTRODUCTION 
 
 
Diabetes  
 
First described 3000 years ago by the Egyptians, it would take another 
millennium before the Ancient Greek physician Araetus of Cappodocia (81-133AD) 
named the disease “diabetes” (Ahmed 2002).  In 1776, English physician and 
experimental physiologist Matthew Dobson first identified the sugar found in the urine 
of diabetic patients, yet was unsuccessful in finding a dietary remedy for the disease 
(Luderitz 1993). The first real therapeutic was realized in 1921, with Frederick 
Banting and Charles Best’s administration of insulin to diabetic patients, yet close to a 
century later diabetes still threatens the lives of those afflicted (Luderitz 1993). 
As of 2013, 382 million people worldwide were living with diabetes, with 46% 
of these people remaining undiagnosed (Aguiree et al. 2013). This number is expected 
to increase drastically in the coming decades, with current estimates placing the global 
total at 592 million by 2035. Currently, 80% of people with diabetes live in low- and 
middle-income countries, and the rising population in the developing world accounts 
for the majority of the expected increase in diabetes diagnoses. The predicted surge in 
diabetes prevalence in Africa (109%), the Middle East and North Africa (96%) and 
South-East Asia (71%) from 2013 to 2035 is particularly worrying, as the associated 
mortality under the age of 60 in these areas is 76%, 50% and 55% respectively 
(Aguiree et al. 2013).  
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Each year, diabetes is directly accountable for 5.1 million deaths, a loss of one 
human life every six seconds. The long-term, progressive nature of the disease results 
in a massive burden for healthcare systems worldwide; diabetes is the foremost cause 
of end-stage renal disease, non-traumatic loss of limb, and blindness in working adults 
(Shulman 2014). It generates a current 11% (548 billion USD) of total healthcare 
spending worldwide with 263 billion from the US alone, a total further expected to 
reach a global level of 627 billion USD by 2035 (Aguiree et al. 2013).  
Diabetes is a multifaceted and heterogeneous disorder. It can broadly be 
divided into two separate diseases, commonly referred to as Juvenile or Type 1 
Diabetes and Adult Onset or Type 2 Diabetes. Type 1 diabetes (T1DM) occurs 
predominantly in patients under 18 years of age and is caused by an autoimmune 
destruction of the insulin-producing pancreatic beta cells, resulting in a deficiency in 
insulin secretion. Without insulin, patients fail to remove glucose from their blood, 
leading to a drastically elevated blood glucose level known as hyperglycemia.  
Patients with T1DM require daily insulin administration to control blood glucose 
levels, without which they will die.  
Type 2 diabetes (T2DM) is far more prevalent, and is typically seen in 
overweight adults, although it is becoming more common in adolescents and children. 
Unlike in T1DM, Type 2 diabetics can still produce insulin, but the production is 
either insufficient or the body cannot properly respond to its release (Polonsky 2012). 
The most important factors associated with T2DM are obesity, high-fat and high-
calorie “Western” diets and sedentary lifestyle. The increase of these factors 
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throughout the world have led to the drastic increase in type 2 diabetes over the past 
half century.  
Insulin signaling is required to maintain a proper blood glucose level. Release 
of insulin when blood sugar levels rise promotes glucose uptake in the muscle and fat 
while inhibiting glucose production in the liver. A dysregulation of this signaling 
pathway leads to a breakdown in blood glucose control, ultimately resulting in 
hyperglycemia (Saltiel & Kahn 2001). Insulin resistance represents a lack of adequate 
response to insulin signaling, and while not yet fully understood, multiple causes have 
been implicated including phosphorylation insufficiencies of the insulin receptor 
protein and IRS and PiP-3 kinase substrates, ectopic lipid accumulation, endoplasmic 
reticulum stress and activation of the unfolded protein response, as well as a complex 
interplay of inflammatory pathways (Wilcox 2005; Samuel & Shulman 2012). 
Compensatory increases in insulin secretion can initially curtail some of the early loss 
of signaling, but ultimately pancreatic beta cell failure results in a loss of glucose-
dependent insulin secretion, further exacerbating the dysfunction of blood glucose 
homeostasis (Ashcroft & Rorsman 2012). 
 
Diabetic Retinopathy – History and Therapy 
 
Retinopathy and visual dysfunction have always been linked to diabetes, with 
20% of diabetic patients developing proliferative retinopathy after 30 years despite 
intensive glycemic control (Nathan et al. 2009). In low- and middle-income countries, 
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where monitoring and treatment options are limited, this poses an even greater 
problem. 
The clinical features of diabetic retinopathy, detectable by early 
ophthalmoscopy, were first described in the 19th century. Early microaneurysms lead 
to abnormal exudation, including the leakage of both hard lipoprotein and blood, 
resulting in macular edema. Ischemia, intraretinal microvascular abnormalities and 
dilatation of venules precede proliferative changes in the retina and vitreous 
hemorrhage.  These changes manifest in the early non-proliferative stage as impaired 
contrast sensitivity, dark adaptation and disturbances to the visual field that cause 
particular trouble with reading and driving at night (Antonetti et al. 2012).  Further 
visual loss is experienced in the proliferative stage as improperly formed new vessels 
disrupt retinal function.  
Treatment by pituitary ablation fell out of favor in the 1960s due to a wide 
array of potential risks and was replaced with the development of panretinal 
photocoagulation. This technique uses hundreds of pinpoint laser burns with the 
intention of reducing retinal oxygen demand and destroying dead tissue to prevent 
further neovascularization within the eye. While effective in preventing additional 
vision loss in some patients, it cannot reverse current degeneration.  
In the early 1990s it was discovered that vascular endothelial growth factor 
(VEGF) drove neovascularization in hypoxia (Miller et al. 1994; Shweiki et al. 1992). 
Based on these findings, a seminal study concluded that patients with diabetic 
retinopathy had elevated VEGF levels in vitreous samples, thus implicating VEGF as 
a driving cause of retinal neovascularization in proliferative diabetic retinopathy 
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(Aiello et al. 1994). With this result, VEGF became a therapeutic target, resulting in 
the development of Ranibizumab (Lucentis) for the treatment of diabetic-related 
ocular dysfunction (NLM Identifier: NCT00445003). Approved for the treatment of 
diabetic macular edema in 2012, this anti-VEGF monoclonal antibody fragment was 
derived from the angiogenesis inhibitor Bevacizumab and functions to inhibit 
angiogenesis by removal of the VEGF signaling molecule (Gupta et al. 2013). Results 
were positive, with reduction of edema and visual degeneration. Many patients 
unfortunately fail to see benefit from Ranibizumab, and the side effect profile of this 
monthly intervitrial injection leaves something to be desired as well as its cost at a 
price of $2000 USD per monthly dose. Furthermore, increased VEGF presence in the 
eye is indicative of hypoxia and retinal dysfunction, and the removal of this signaling 
protein fails to treat the underlying cause of vision loss. 
 
 
Diabetic Retinopathy – A Deeper Understanding 
 
The metabolic abnormalities of the pre-diabetic and diabetic state cause 
damage to the surrounding tissue through various and complicated mechanisms. Most 
research into the etiology of this damage has focused on circulating high blood 
glucose, yet elevated levels of free fatty acids (FFA), insulin resistance and 
hyperinsulinemia are all known to play different yet related roles. Together, these 
alterations drive vasculopathy and cause changes to endothelial function throughout 
the body (Zhang et al. 2011).  The effects vary by the tissue affected, but often include 
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attenuation of endothelium-mediated vasomotor function, increased endothelial 
apoptosis, promotion of endothelium activation/endothelium–monocyte adhesion, 
upregulation of an atherogenic response and the decrease of proper barrier function 
(Zhang et al. 2011). A multitude of signaling pathways underlie these detrimental 
modifications driven by glucotoxicity and abnormal insulin signaling. Furthermore, 
FFA level increases are known to further promote insulin resistance and increase 
inflammation and oxidative stress. These factors act not only individually, but also 
synergistically, hastening the feed-forward cycle of endothelial damage to the ultimate 
demise of the surrounding tissue nourished by this blood flow.   
Michael Brownlee pioneered early research into the damaging effects of 
hyperglycemia-driven microvascular pathology in the diabetic eye. Hyperglycemia 
creates abnormalities in blood flow and disrupts proper vascular permeability by 
altering vasoregulatory elements. Permanent increases in permeability drive cell death 
which results in improper perfusion (Brownlee 2001). Such alterations result in 
edema, ischemia and hypoxia, and ultimately a compensatory neovascularization and 
visual degeneration. This endothelial disruption, caused by hyperglycemia and insulin 
resistance, is driven by four unique pathways that some believe underlie diabetes-
induced damage to the eye. Increased polyol pathway flux coupled with an activation 
of protein kinase C can lead to a plethora of destructive changes including blood flow 
abnormalities mediated by eNOS and ET-1, vascular permeability changes via VEGF 
secretion, capillary occlusion through TGF-β, pro-inflammatory gene expression by 
NF-κB and an increase in ROS generation (Brownlee 2001; Giacco & Brownlee 
2010). Separate from the above, Brownlee further demonstrates hyperglycemia-driven 
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increases in advanced glycation end products (AGEs) which damage cells in three 
important ways: altered protein function, abnormal modifications to the extracellular 
matrix and AGE receptor activation, all leading to pathological damage which is 
partially preventable by AGE inhibition (Soulis-liparota et al. 1991; Nakamura et al. 
1997). Finally, an increased flux through the hexosamine pathway results in 
detrimental changes to gene and protein expression, which, along with the other three 
hyperglycemia-induced alterations, contributes to the pathology of diabetic 
retinopathy. More recent research has brought doubt to this hypothesis, as blocking a 
number of these pathways fails to reverse endothelial damage and end-organ 
dysfunction, as well as the fact that degeneration can occur earlier than pronounced 
blood sugar levels. 
Renu Kowluru has furthered the understanding the diabetes-driven oxidative 
and inflammatory damage in the eye, focusing on impairment of the retinal 
microvasculature and the subsequent increases in reactive oxygen species (ROS) 
(Madsen-Bouterse et al. 2010). Noting that an imbalance in the production and 
removal of ROS damages DNA, lipids, proteins, and carbohydrates, disrupts cellular 
homeostasis and induces permeability of mitochiondria, all of which leads to cellular 
failure underlying diabetic retinopathy (Kowluru & Chan 2007).  This inflammation 
and oxidative stress causes damage to the mitochondria, reducing the ability of cells to 
generate an adequate level of ATP needed to maintain primary cellular functions 
(Kowluru 2005).  The increased flux of glucose through the mitochondria leads to an 
overproduction of superoxide, commencing a cascade of damage from the production 
of more superoxide, hydrogen peroxide, hydroxyl radicals, and peroxynitrite which 
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further damage macromolecules either at or near the site of their formation (Bergamini 
et al. 2004).  
Further insight into the development of early diabetic retinopathy has focused 
on the microvasculature of the eye, specifically the choroidal vasculature of the outer 
retina. The retina is extremely metabolically active, with 90% of the oxygen provided 
by the choroidal vasculature and only 10% by the inner retina’s vascular supply 
(Nickla & Wallman 2011). For the requisite oxygen concentrations to reach the 
photoreceptors, a very steep oxygen gradient is required. For this to occur, the blood 
flow in the delicate choroidal capillaries is most likely the highest of any tissue in the 
body per unit tissue weight, with a rate approximately an order of magnitude higher 
than the brain (Nickla & Wallman 2011). The choroidal vasculature is especially 
affected by metabolic syndrome and high-fructose diet, where fructose-fed rats 
exhibited choroidal damage and neovascularization to a significantly increased degree 
(Thierry et al. 2014). Even before hyperglycemia, insulin resistance damage causes 
disruption and endothelial dysfunction, and the choroid may be particularly 
susceptible (Mather et al. 2013; Zhang et al. 2012).  
The disruption of insulin signaling, either through insulin resistance or altered 
insulin levels, has been implicated in endothelial dysfunction through perturbations of 
sensitive vasoregulatory systems (Zhang et al. 2012). These alterations occur very 
early in the progression of diabetes, even before hyperglycemia.  Insulin induces the 
release of counteracting factors including endothelin-1 (ET-1), leading to 
vasoconstriction, and nitric oxide (NO), leading to vasodilation (Potenza et al. 2009). 
Disruption of NO signaling in particular, as evidenced by depleted levels of 
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endothelial nitric oxide synthase (eNOS), prevents proper vasodilation leading to 
occlusion and a reduction in the blood flow necessary to sustain RPE and 
photoreceptor function (Potenza et al. 2009; Vicent et al. 2003).  Furthermore, 
alterations to insulin signaling can produce structural changes to the vasculature, 
including increased basal membrane thickness and improper matrix crosslinking, 
resulting in a loss of permeability and barrier function (Bakker et al. 2009). Reduction 
of the vasoregulatory capability of the microvasculature leads to a failure to 
adequately respond to stimuli, limiting the delivery of oxygen, nutrients and hormones 
critical for visual function. Insulin signaling disruption additionally creates an increase 
in inflammation, resulting in oxidative stress and the subsequent damage of tissues and 
apoptosis of both endothelial, pericyte and retinal cells (Kowluru & Chan 2007; 
Bakker et al. 2009). Premature vascular senescence resulting in reduced endothelial 
vasoregulatory capability and susceptibility to inflammation and oxidative stress, has 
also been linked to insulin resistance and high fat diets in rats (Chen et al. 2007). Thus, 
the insulin resistance-induced disruption of the critical choroidal blood supply creates 
an ischemic and hypoxic outer retina, ultimately resulting in degeneration of the retina 
and corresponding visual dysfunction. 
 
 
The Mitochondria in Diabetic Retinopathy 
 
Mitochondria are cellular organelles primarily responsible for the generation of 
adenosine triphosphate (ATP), the energy currency of the cell. An outer mitochondrial 
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membrane (OMM) surrounds an intricately folded inner mitochondrial membrane 
(IMM), which houses the protein complexes of the electron transport chain (ETC). To 
generate energy from glucose, the sugar follows a complex metabolic pathway 
involving its conversion to pyruvate (via glycolysis), acetyl CoA (via pyruvate 
dehydrogenase) and finally CO2 (via the TCA or citric acid cycle), which generates 
the electron-carrying products NADH and FADH2. These products donate their 
electrons to drive the ETC, where four complexes couple redox reactions with the 
pumping of protons (H+ ions) into the intermembrane space between the OMM and 
IMM. The energy obtained from this proton gradient, the proton motive force, is used 
by the fifth and final complex, ATP synthase, to generate ATP from ADP and an 
inorganic phosphate. Known as oxidative phosphorylation, this process produces the 
majority of cellular energy in aerobic conditions and can utilize not only sugars, but 
products from fatty acid oxidation and amino acid oxidation as well.  
This implication of the mitochondria as a critical underlying focus in the 
etiology of diabetes is not new, as mitochondrial dysfunction is a hallmark of multiple 
diabetic complications. Recent studies have implicated a mitochondrial role in the 
etiology of diabetes even before hyperglycemia (Du et al. 2003; Kowluru et al. 2011). 
Brownlee’s hypothesis of mitochondrial overproduction of ROS is based on an 
increased concentration of glucose-derived pyruvate feeding unsustainable amounts of 
electron donors into the ETC. Electrons fail to flow through the complexes properly, 
backing up at coenzyme Q where they’re donated to O2, thus generating superoxide 
(Giacco & Brownlee 2010). Superoxide can be converted to H2O2 by superoxide 
dismutase, and both these radical oxygen molecules can cause cellular damage to the 
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surrounding mitochondria. Uncoupling proteins, which allow H+ ions to cross the 
IMM and thereby destroy the proton gradient, can prevent the increase in ROS 
generation (Du et al. 2001). This has recently been contested, however, where reduced 
superoxide generation is seen in diabetic tissue due to suppressed mitochondrial 
activity via reduced AMP-activated protein kinase (AMPK) activity (Dugan et al. 
2013). Furthermore, pharmacological activation of AMPK led to an increase in 
superoxide production and a beneficial reduction of pathophysiological characteristics 
(Dugan et al. 2013). This newer line of reasoning is supported in separate studies that 
found decreased, not increased mitochondrial oxidative phosphorylation in diabetic 
tissues (Mootha et al. 2003).  
Mitochondrial hormesis is the theory of increased ROS within the 
mitochondria initiating a compensatory cellular response that improves stress 
resistance (Ristow & Zarse 2010). Built from theories of caloric restriction and 
reduced glucose metabolism, hormesis has been demonstrated as a novel therapeutic 
route, whereby AMPK activation and thus the restoration of superoxide and 
mitochondrial function has been associated with improvement in diabetic dysfunction 
(Sharma 2015). ROS serve a multitude of roles as critical endogenous messengers, and 
it appears that early work implicating elevated ROS levels for diabetic dysfunction 
was oversimplified, and in some cases, completely incorrect. 
Insulin resistance has been shown to produce detrimental effects to 
mitochondrial function in both skeletal muscle and the heart (Sleigh et al. 2011; 
Szendroedi et al. 2011). Furthermore, cardiac mitochondrial deficiencies persist 
irrespective of elevated HbA1c or blood glucose levels (Croston et al. 2014). 
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Morphological changes to pancreatic β-cell mitochondria before and after the onset of 
hyperglycemia correspond with altered membrane potential and respiratory capacity 
with a decrease in cellular ATP content (Lu & Koshkin 2010). The remodeling of 
cardiolipin, a mitochondrial phospholipid essential for the control of membrane 
dynamics and the organization of respiratory complexes, has been documented in 
diabetic cardiomyopathy (Houtkooper & Vaz 2008; He & Han 2014).  Peroxidation of 
this crucial phospholipid in diabetic models leads to a decrease in oxidative 
phosphorylation and the facilitation of cytochrome c detachment, an initiating event of 
the apoptotic pathway (Ferreira et al. 2013).  
Recently, a new understanding of mitochondrial failure termed “metabolic 
inflexibility” has been elucidated. Mitochondria must change energy sources 
depending on a variety of stimuli and alternative fuel availability. In models of 
metabolic syndrome, however, nutrient overload and heightened substrate competition 
can overwhelm the delicate network of crosstalk responsible for proper regulation of 
mitochondrial energy generation (Muoio 2014). Diabetic patient’s mitochondria fail to 
satisfactorily alter substrate consumption, whereas healthy patient’s mitochondria 
properly shift from fatty acid oxygenation to glucose oxidation after a high-
carbohydrate meal (Kelley et al. 1999). Drastic substrate excess overwhelms signaling 
pathways regulating optimal substrate use, resulting in inflexibility and a suboptimal 
utilization of fuels, ultimately leading to functional changes in the cell and tissue 
including alterations of insulin action, glucose disposal, lipolysis, lipid storage, 
immune function, and inflammatory responses (Muoio 2014).  This inflexibility has 
been linked to alterations to insulin action, glucose disposal, lipolysis, lipid storage, 
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immune function, and inflammatory response, all of which hasten the development of 
end organ dysfunction. 
Mitochondrial abnormalities are notable in diabetic retinopathy as well. In the 
early stages of the disease, mitochondrial dysfunction is evident even before 
histopathological abnormalities arise (Kowluru et al. 2011). Alterations to 
mitochondrial structure, including swelling and loss of cristae are seen in animal 
models and human patients, as well as an accumulation of defects in mitochondrial 
DNA (mtDNA) and a deficit in transport protein levels, with cessation of 
hyperglycemia failing to reverse these changes (Zhong & Kowluru 2011; Madsen-
Bouterse et al. 2010; Santos & Kowluru 2013). Similar swollen mitochondria are seen 
in hyperglycemic retinal ganglion cells before apoptosis, while impaired mitochondria 
within the retinal pigment epithelium (RPE) are associated with an increased 
sensitivity to oxidative stress, lowered ATP levels and impaired autophagic and 
phagocytic capacities of shed photoreceptor outer segments (Xie et al. 2008; He et al. 
2011; Schütt et al. 2012). Mitochondrial swelling and a loss of cristae are commonly 
seen in hypoxic conditions (Zhao et al. 2004; Liu et al. 2014). The enlarged, cristae-
deficient mitochondria found in the RPE indicate the presence of a similar hypoxic 
environment, potentially caused by reduced blood flow following damage to the 
choroidal microvasculature. Impaired mitochondria drive the feed-forward cycle of 
oxidative damage and inadequate ATP production, which robs the cell’s endogenous 
antioxidant defense capabilities of the requisite energy to preform adequately, thereby 
creating even more damage. This bioenergetic failure is a critical component of 
diabetic retinopathy, due to the specialized nature of the retina. 
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The RPE’s critical role within the eye 
 
There is one cellular layer in particular that has become the target of interest in 
degenerative vision disorders: the retinal pigment epithelium (RPE). The RPE is a 
highly metabolically active single cell layer separating the outer retina from the blood 
supply of the choroid. It performs a number of interrelated jobs, each crucial to visual 
function (Strauss 2005). Beyond the adsorption of light passed though the retina, the 
RPE plays a critical role in the caretaking of overlaying photoreceptors, of which each 
RPE cell is responsible for 15-50 photoreceptors (Kennedy et al. 1995; Snodderly et 
al. 2002). Each day, 10-15% of the photoreceptor outer segment is shed, with the RPE 
responsible for its phagocytization, digestion and the recycling of essential 
components (Snodderly et al. 2002). This recycling capacity further extends to the 
reisomerization of all-trans-retinal to 11-cis-retinal, without which the visual cycle 
ceases (Strauss 2005).  The RPE additionally serves to ensure photoreceptor action by 
stabilizing the ionic composition of the subretinal space, allowing for adequate 
photoreceptor excitability.  Maintenance of proper choriocapillary endothelium and 
photoreceptor integrity is dependent on the secretion of neurotrophic, adhesion, and 
vascular regulatory factors from the RPE, a disruption of which is implicated in visual 
dysfunction (Ambati & Fowler 2012). VEGF secretion in particular is critical to 
proper maintenance of the choroidal endothelium, and an upregulation of this 
signaling is the driving cause of neovascularization in DR via VEGFR activation 
(Costa & Soares 2013; Kurihara et al. 2012). The RPE acts as an active barrier to the 
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outer retina, controlling and supporting the flow of essential nutrients from the 
choroidal blood supply to the photoreceptors (glucose, retinal), and from the subretinal 
space to the blood (ions and water). This process is supported by the intricate 
basolateral infoldings, creating a large surface area for proper transport to occur. The 
removal of water, a byproduct of metabolism from the photoreceptors and neurons, is 
critical, as a failure of this action leads to macular edema, the hallmark of early 
diabetic retinopathy (Strauss 2005; Kovach & Schwartz 2009). Mitochondrial failure 
within the RPE thus results in a bioenergetic failure. This failure impairs the cell 
layer’s tight-junction formation and therefore the integrity of the blood/retina barrier, 
prevents the epithelial transport necessary for the uptake of retinal and ω-3 fatty acids 
required for photoreceptor function, and impedes the removal of metabolic end 
products. Furthermore, such bioenergetic failure reduces the phagocytic capability 
required for sustaining the visual cycle and the secretory capabilities required to 
preserve the microvasculature and immune privilege of the eye (Strauss 2005; Duh 
2008) 
 
 
Current approaches for the treatment of diabetes  
 
 There are multiple pharmacological therapies intended to restore proper blood 
glucose levels and prevent the end-organ complications associated with diabetes. The 
first such therapeutic is insulin itself, which began human trials in 1922. Administered 
either via injection or insulin pump, insulin is effective in controlling hyperglycemia 
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and has no upper limit in dosage for therapeutic effect (Skugor 2014). Daily injection, 
however, is complicated for some patients and is usually considered as a “last resort” 
by physicians (Funnell 2007). 
Additional pharmacologic therapies have been developed in order to provide 
alternative or additional support with blood glucose regulation. The 
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor gamma 
(PPARγ) agonists that function to partially restore insulin sensitivity to muscle and fat. 
Activating this nuclear receptor favorably alters the transcription of several genes 
involved in glucose and lipid metabolism and energy homeostasis (including AMPK), 
restoring lost sensitivity to endogenous insulin signaling. Approved for T2DM, the 
first drug in this class	  Troglitazone (Rezulin) was withdrawn from the US market in 
2000 after its adverse hepatic effects became known. Another drug, Rosiglitazone 
(Avandia), has been implicated in cardiovascular events and was placed under sales 
restrictions, but the FDA reversed this decision in 2013. 
A second class of antidiabetic drugs for T2DM are the Biguanides, especially 
Metformin (Glucophage); the first-choice drug for obese and overweight patients 
currently prescribed to 100 million patients worldwide (Rena et al. 2013). T2DM 
patients have increased rates of endogenous hepatic glucose production, and 
metformin functions to reduce this gluconeogenesis (Hundal et al. 2000). The exact 
mechanism is yet to be fully elucidated, yet includes inhibition of complex I of the 
mitochondrial respiratory chain, activation of AMPK, potentially through an increase 
in the AMP:ATP ratio, and alterations to the gut microbiome (Rena et al. 2013; 
Burcelin 2013). Furthermore, metformin increases insulin sensitivity as well as insulin 
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receptor binding of insulin, and enhances peripheral glucose uptake (Baily & Turner 
1996). 
The third common class of antidiabetics is the Sulfonylureas, which function 
by promoting the release of insulin. Often coupled with other antidiabetic agents, these 
drugs bind to ATP-sensitive K+ channels on pancreatic beta cells, depolarizing the 
cells, thus stimulating an increase in intracellular Ca2+ concentrations and the fusion of 
insulin granulae with the cell membrane and the release of insulin. 
An additional class of therapeutics for diabetes is the Glucagon-Like Peptide-1 
(GLP-1) mimetics, which mimic endogenous GLP-1 by increasing the post-prandial 
release of insulin and inhibiting glucagon release. These drugs have been further 
demonstrated to reduced inflammation of endothelial cells and activate AMPK, 
thereby protecting the bioenergetics of the vasculature (Krasner et al. 2014). 
Alternative treatments have focused on the mitochondrial etiology of the 
disease and have thus viewed mitochondrial protection as a means to prevent end-
organ dysfunction. The most researched of these is MitoQ, a ubiquinone moiety linked 
to a triphenylphosphonium (TPP) cation by a ten-carbon alkyl chain. TPP is thus used 
as a lipophilic cation to deliver ubiquinol to the mitochondria where it functions as an 
antioxidant, preventing lipid peroxidation and damage from peroxynitrite and 
superoxide (Smith & Murphy 2011). Promising results have been demonstrated in 
animal models of mitochondrial oxidative damage, yet MitoQ failed in its only Phase 
II trial in 2010 (NCT01167088). 
More recent studies have also found potential for other mitochondria-targeted 
therapeutics. TT01001, a novel ligand of the OMM protein mitoNEET, has been 
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demonstrated to restore proper glucose metabolism and mitochondrial function in a 
diabetic mouse model (Takahashi et al. 2014). The AMPK-activating compound 5- 
aminoimidazole-4-carboxamide riboside (AICAR) has been demonstrated to 
ameliorate glucoregulatory defecits and attenuate hyperglycemia-induced effects in 
animal models, as well as reduce hepatic glucose output, lower blood glucose levels 
and reduce plasma FFA concentrations in human subjects (Winder 2009; Boon et al. 
2008). 
 
 
A novel strategy  
 
Combating visual degeneration by protecting the RPE has been attempted in a 
myriad of ways, yet no treatment has proven useful to human patients.  Here, we 
investigated the use of SS-31 (MTP-131, Bendavia, Ocuvia) as a potential therapeutic 
to combat DR via mitochondrial protection.  
Discovered serendipitously during synthetic opioid research, the Szeto-Schiller 
(SS) peptides are highly polar, water-soluble, four amino acid long peptides with 
remarkable cell permeability (Szeto & Birk 2014).  Despite a 3+ charge, high 
molecular weight (640 kDa) and polar peptide backbone, an SS peptide (a fluorescent 
analog of SS-02) was taken up by numerous cell types and localized to the 
mitochondria (Zhao et al. 2004). The uptake does not rely on mitochondrial potential, 
unlike TPP-based compounds (eg: MitoQ), and selectively partitions to the IMM with 
little presence elsewhere in the mitochondria, all without causing mitochondrial 
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depolarization (Zhao et al. 2004). Among this class of peptides is SS-31 (H-d-Arg-
Dmt-Lys-Phe-NH2, also known as MTP-131 as a acetate salt, or “Bendavia”), which 
has been demonstrated to selectively target the mitochondrial phospholipid 
cardiolipin, which is present exclusively on the IMM (Birk et al. 2013).  Alterations to 
cardiolipin, including its oxidation and depletion, deleteriously impact the membrane 
curvature necessary for proper cristae formation (Acehan et al. 2007). Through both 
electrostatic and hydrophobic interaction with cardiolipin, SS-31 localizes to the inner 
mitochondrial membrane and prevents cardiolipin peroxidation and promotes proper 
cristae formation, allowing adequate respiratory complex association (Szeto 2014). 
This optimization of respiratory complex assembly and function optimizes the ETC, 
reducing the generation of ROS while improving electron transfer and thus ATP 
production. 
 SS-31 has shown promise in combating cellular deterioration in disease states 
associated with bioenergetic failure, including animal models of ischemia-reperfusion, 
age-related muscle weakness, kidney failure and neurodegeneration (Birk et al. 2013; 
Siegel et al. 2013; Eirin et al. 2012; Yang et al. 2009). There has been a focus on 
research of ischemic and hypoxic disease states, such as in ischemic heart injury 
where SS-31 was shown to protect cardiac mitochondria and improve myocardial ATP 
synthesis, and in transverse aortic constriction-induced heart failure where similar 
mitochondrial protection was proteomically observed (Dai et al. 2013; Sabbah et al. 
2013). Similar results were seen in isolated perfused hearts, where SS-31 treatment 
decreased total heart lipid peroxidation and preserved ATP content (Szeto 2008). 
Prevention of the deleterious effects of ischemia was further demonstrated in a renal 
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artery occlusion model, where SS-31 maintained mitochondrial structure and ATP 
production, as well as decreased lipid peroxidation and tubular apoptosis (Szeto et al. 
2011). SS-31’s mitochondrial protective effects during ischemia have been recognized 
to protect microvasculature during energy and oxygen deficiency. In a renal artery 
stenosis model treated with SS-31 during the renal angioplasty, a reduction in 
oxidative stress, fibrosis and microvascular rarefaction was seen four weeks later 
(Eirin et al. 2012). Similar microvascular-protective effects were demonstrated in 
attenuation of no-reflow effects in a rabbit model, even with SS-31 dosage after the 
onset of ischemia (Kloner et al. 2012). This SS-31-based protection of the 
microvasculature and subsequent preservation of organ function after blood flow 
deprivation was further demonstrated in rat model of acute renal ischemia where 
protection of endothelial mitochondria prevented inflammatory and fibrotic damage 
typical of tissue hypoxia (Liu et al. 2014). This microvascular-protective effect in 
hypoxic conditions provides a well-supported basis for SS-31’s investigation in 
diabetic retinopathy, a disease where microvascular dysfunction drives visual 
degeneration. 
SS-31 has been further shown to block the development of insulin resistance in 
the skeletal muscle of mice fed a high-fat diet while reducing H2O2 emission and 
preventing the increase in GSSG and decrease in GSH/GSSG ratio in response to 
glucose ingestion (Anderson et al. 2009). The link between mitochondrial 
bioenergetics protection and insulin sensitivity, coupled with SS-31’s proven ability to 
protect microvasculature and therefore the functionality of the surrounding tissue, 
positions it to fill an unmet need in the treatment of diabetic retinopathy. 
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A preliminary study found SS-31 to protect the inner retina from oxidative 
stress after a four-week daily injection in an STZ model (Huang et al. 2013). 
Eneucleated eyes showed improved distribution of claudin-5 and occludin, as well as 
decreased retinal leakage in an Evans blue assay; all indicating SS-31 preserved the 
integrity of the microvasculature. SS-31 has additionally been documented to protect 
cultured human lens cells against oxidative stress (Cai et al. 2014). Importantly, we 
have now linked these observations regarding retinal blood supply failures to 
functional visual measurements, confirming their findings that SS-31 exerts a 
protective effect in the eye.  
A topical, eye drop formulation of SS-31 has been created in order to facilitate 
treatment. Despite SS-31’s 3+ net charge, excellent corneal penetration was achieved. 
Rapid intraocular wall distribution was observed with high levels of SS-31 in the 
anterior compartment (conjunctiva, cornea and sclera), indicating potential uptake via 
the episcleral veins of the conjunctival epithelium. With low drug concentrations 
observed in the vitreous, it is likely that the drug is absorbed systemically and thus 
distributes to the posterior compartment of the eye through blood circulation to the 
choroid and RPE. Peak blood levels occur after 2 hours, with peak levels in the 
choroid and retina following at 4 hours post application. 
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Table 1. Distribution of [14C] SS-31 in New Zealand white rabbits in ocular tissues. 
Rabbits are >12 weeks of age, 2.5 – 3.43 kg, n>3. 
 
 
 
Measurement of vision 
 
A variety of visual deficits are among the earliest symptoms of diabetic 
retinopathy, often occurring ahead of detectable vascular lesions or macular edema 
(Jackson et al. 2012). Functional deficits, including color perception, loss of blue-
sensitive color vision, and reduced dark adaptation are present before alterations to the 
microvasculature or retinal structure (Hardy et al. 1992; Henson & North 1979; Daley 
et al. 1987; Jackson et al. 2012). Visual function in animal models of diabetes, as 
measured by optokinetic tracking (OKT), shows a loss of visual acuity as early as 3 
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weeks and contrast sensitivity within 9 weeks after STZ treatment when controlling 
for cataract formation, all before detectable physical lesions including vascular 
leakage, pericyte dropout, and acellular capillaries (Aung et al. 2013; Kirwin et al. 
2011)  
Visual degeneration can be detected through the sensitive assessment 
technique of optokinetic tracking. Developed by Glen Prusky, this practice utilizes a 
rotating virtual cylinder to assess both contrast sensitivity and spatial frequency 
(Prusky et al. 2004). Here, we utilize this technique in order to assess the degeneration 
of vision in models of diabetes in mice, as well as the utility of SS-31.  
We have carefully selected a model mouse to recapitulate the human early 
diabetic phenotype for this retinopathy study. Our model combines a moderate dose of 
streptozotocin in order to destroy a fraction of the pancreatic beta cells and thus reduce 
insulin secretion. More importantly, the high-fat diet, begun at an early age, induces 
insulin resistance and ultimately glucose intolerance, hyperglycemia and weight gain.  
Vasculopathy develops, and the choroidal blood flow ceases to support the outer 
retina, resulting in visual degeneration without requiring genetic manipulation. 
 
The work in this thesis presents a deeper understanding of diabetic retinopathy, 
combined with positive results from a novel therapeutic tailored to this new 
understanding. Using a mitochondria-targeted therapeutic to halt the feed-forward 
cycle of bioenergetics breakdown protects the retina’s vasculature and RPE, allowing 
the retina-sustaining functions to resist failure. Protecting these vital sections of the 
retina, without reversing hyperglycemia, weight gain and insulin resistance shows 
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promise in a disease that threatens the vision of hundreds of millions of people. 
Reversing or preventing the loss of contrast sensitivity and visual acuity, events that 
occur before the larger-scale edema and neovascularization, represents a paradigm 
shift in the treatment of diabetic retinopathy. Formulated into a topical ophthalmic 
solution (“Ocuvia™”) a phase 1/2 clinical trial (NCT02314299) has begun with an 
estimated completion date of July 2015. 
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ABSTRACT 
 
Subtle changes in the neural retina can be detected much earlier than retinal 
vasculopathy in diabetic retinopathy. In mice fed a high fat diet, we have found early 
and progressive decline in visual acuity, as measured by optokinetic tracking, even 
before significant weight gain and hyperglycemia. Fundus examination was normal 
and fluorescein angiography showed normal retinal vasculature. The only major 
histologic findings were swollen mitochondria, edema and degenerative changes in the 
retinal pigment epithelium (RPE). Outer retinal ischemia and inflammation are 
supported by elevated VEGF, TNFa, MCP-1, and choroidal neovascular tufts. 
Treatment with a mitochondria-targeted tetrapeptide (SS-31/MTP-131) reversed visual 
decline without reducing blood glucose, body weight or insulin resistance. SS-31 is 
known to target cardiolipin and promote electron transfer and ATP synthesis. SS-31 
preserved mitochondrial morphology and integrity of the RPE, reduced inflammatory 
markers, and prevented choroidal neovascularization. These results demonstrate a 
causal relationship between RPE mitochondrial energy failure and loss of visual acuity 
in early metabolic syndrome, and support a bioenergetics-based approach for 
preventing diabetic complications. A topical formulation of SS-31 (OcuviaTM) is in 
Phase 2 clinical trial for diabetic macula edema and non-proliferative age-related 
macular degeneration. 
 
 
 
 
 
 
 
 
 
 
 
 42 
INTRODUCTION 
 
Diabetic Retinopathy (DR can manifest as diabetic macular edema in the non-
proliferative phase, and retinal neovascularization with vascular hemorrhage in the 
proliferative phase. Intensive metabolic control reduces the incidence and progression 
of DR, but proliferative DR still develops in up to 20% of persons with diabetes 
despite intensive metabolic control (1). Vascular endothelial growth factor (VEGF) 
has been implicated in the pathogenesis of macular edema and neovascularization, and 
agents that block VEGF are currently the most effective treatment for DR when 
metabolic control is insufficient. Although these anti-VEGF therapies are effective in 
regression of neovascularization in some patients, they only provide small gains in 
visual acuity and require repeat intravitreal injections with the additional concern of 
systemic adverse effects due to the pleiotrophic actions of VEGF.  
 
There is growing recognition that retinal dysfunction and impaired visual 
behavior, including loss of contrast sensitivity and dark adaptation, are present in 
human patients and diabetic animal models before retinal vascular changes become 
evident (2-7). Furthermore, abnormal electroretinography (ERG) has been found in 
both type 1 and type 2 diabetics who have no clinical vascular lesions, as well as 
diabetic animal models (6; 8; 9). We recently reported very early decline in spatial 
visual function in a mouse model of high fat feeding (10). Reduction in spatial 
frequency and contrast sensitivity was apparent after just 4 weeks of high-fat diet 
(HFD), before there was any increase in blood glucose. Abnormal glucose tolerance 
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tests (GTT) suggest that the onset of visual function may be associated with insulin 
resistance rather than glucose toxicity. However, the addition of a modest dose of STZ 
(HFD+STZ) potentiated the rate and magnitude of visual degeneration in HFD mice, 
suggesting a synergistic mechanism between insulin resistance and hyperglycemia. 
 
Hyperglycemia, by increasing substrate flux through mitochondria, increases 
production of reactive oxygen species (ROS), causing oxidative damage to 
mitochondrial lipids and proteins and reducing ATP generation (11-14). As 
mitochondrial damage accrues, endogenous antioxidant systems fail to keep pace with 
elevated ROS levels, creating a feed-forward cycle of oxidative stress. Once this cycle 
has begun, bioenergetics failure in the retinal pigment epithelium (RPE) impairs its 
critical barrier, secretory, transport and visual cycle functions, as well as the 
phagocytic capability required for the daily metabolism of shed photoreceptor outer 
segments, ultimately resulting in loss of visual function and cell death (15). To test the 
hypothesis that mitochondrial dysfunction and oxidative stress may underlie this 
visual decline, we treated both HFD and HFD+STZ mice with the mitochondria-
targeted antioxidant SS-31 (also known as MTP-131) (16; 17). Treatment with SS-31 
after onset of visual decline led to recovery of visual function, while having no effect 
on blood glucose levels, body weight or glucose clearance (10). We further 
demonstrated a similar preservation of spatial frequency and contrast sensitivity 
utilizing a topical ophthalmic formulation of SS-31 (10). These findings suggest that 
SS-31 is acting directly to protect the retina from insulin resistance and glucose 
toxicity. In this study, we report that the decline in spatial visual function is associated 
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with choroidal neovascularization, retinal hypoxia and inflammation, and degeneration 
of the RPE. Treatment with SS-31 preserved the choroidal vasculature and protected 
RPE structure and function, and restored visual function.   
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RESEARCH DESIGN AND METHODS 
 
Animals and Diets 
Experimental procedures on animals were conducted in accordance with the policies 
of the Weill Cornell Medical College IACUC Committee. Male C57BL/6 mice were 
obtained from Charles River Laboratories at 3 weeks of age. They were maintained on 
a 12 hour light/dark cycle. Mice were fed a normal diet (ND; LabDiet Picolab Rodent 
Diet 5053; 4.5% fat, 60% carbohydrate, 20% protein,) or a high-fat diet (HFD; Bio-
Serv Mouse Diet F3282; 36.0% fat, 35.7 % carbohydrate, 20.5% protein) ad libitum 
from 4 weeks of age. Streptozotocin (STZ; 40 mg/kg, i.p.) was administered to HFD 
mice (HFD+STZ) at 8 weeks of age for 5 consecutive days.  
 
Study Design 
Body weight, non-fasted blood glucose, and visual behavior were assessed weekly in 
all mice starting at 4 weeks. A glucose tolerance test (GTT) was administered at 12 
weeks and 30 weeks of age as described previously (10). After the first GTT at 12 
weeks, HFD+STZ mice received either 5 µl of 0.01 M SS-31 (D-Arg-2’6’-
dimethylTyr-Lys-Phe-NH2; Stealth Peptides, Newton, MA) or vehicle (sodium 
acetate, pH 6.0) in each eye daily from 12 to 32 weeks of age.  
 
Test of Spatial Visual Function 
Spatial thresholds for optokinetic tracking (OKT) of sine-wave gratings were 
measured weekly from 4 weeks to 32 weeks of age using a virtual optokinetic system 
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(OptoMotry, CerebralMechanics Inc., Medicine Hat, Alberta, Canada). Details of this 
method can be found in our previous publications (10; 18; 19). A spatial frequency 
(SF) threshold was generated under scotopic conditions (1 lux) through each eye 
separately in a testing session.  
 
Fundus Photography and Fluorescein Angiography 
Fundus images were taken on isoflurane-anesthetized mice at 32 weeks with the 
Micron III system (Phoenix Research Laboratories, Pleasanton, CA). Briefly, the 
pupils were dilated with tropicamide and phenylephrine hydrochloride, followed by 
Goniosoft (Hydroxypropyl Methylcellulose 2.5%) medium for protection. A series of 
5-15 images was taken for each eye. Fluorescein angiography followed the fundus 
protocol. A series of 5-15 images per eye was taken starting 1 minute after 0.05-0.1 ml 
of 2.5% sodium fluorescein (i.p.). Fundus and FA images were graded on a standard 
scale. 
 
Tissue Handling and Histological Evaluations 
Mice were sacrificed by anesthetic overdose and cervical dislocation, followed by 
decapitation and eye excision. For assessment of retinal architecture, eyes were fixed 
in Davidson’s Fixative for two days, followed by post-fixation in 4% 
paraformaldehyde, 2% ZnCl and 20% isopropyl alcohol for >48 h. Eyes were then 
processed by Excalibur Pathology Inc. according to a standard protocol. The H&E 
stained sections were photographed with a light microscope (Zeiss Axio Observer Z1 
with an AxioCam ERc 5s color CMOS camera) and examined for laminar 
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abnormalities. Whole flat mounts of the outer retina were prepared for detailed 
analysis of the RPE monolayer (20).  Briefly, eyes were enucleated and the retinas 
were carefully removed with tweezers. Eye cups were fixed for 1 hour, washed in cold 
ICC buffer and stained for 15 minutes in 1:100 Alexa Fluor® 488 Phalloidin (Life 
Technologies, Carlsbad, CA) and a 1:100 of a 1µg/1µL solution of isolectin IB4 
conjugated with Alexa Fluor 568 (Life Technologies, Carlsbad, CA) in ICC buffer. 
Imaging was accomplished with both a Zeiss Cell Observer SD equipped with dual 
Photometrics Evolve 512 EMCCD cameras on the Yokogawa CSU-X1 confocal 
scanner unit and a Zeiss Axio Observer. Images were stitched together at maximum 
intensity projection with Zeiss Zen software to view the entire flat mount with high 
resolution. Stacks of images spanning the retinal vasculature and RPE, and three-
dimensional images were obtained using Zeiss Zen image analysis software (Carl 
Zeiss AG, Oberkochen, Germany). RPE cell size was quantified using ImageJ 
(National Institutes of Health, Bethesda, MD). Twenty areas were scored from three 
eyes per group, with five representative cells quantified per area. Neovascular tuft 
counts were performed by tallying the number of isolectin-labeled tufts around the 
optic nerve in five flat mounted eyes per group.  
 
Transmission Electron Microscopy (TEM) of Retina 
Eyes were punctured with a fine gauge needle through the pupil, and placed in Yellow 
Fixative on ice for 24 hours then transferred and stored in 0.1M sodium cacodylate at 
RT until being processed. Eyes were immersed in 1% osmium tetroxide for 1 h, 
dehydrated in acetone, stained in 1.5% uranyl acetate for 1 h, and then embedded in 
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Epon. 1µM sections of the block were cut and stained with 0.1% toluene blue, then 
sections were further cut to 70 nM and stained with lead citrate (21). Specimens were 
examined with a digital TEM (JEOL JEM-1400). To calculate mitochondrial cristae 
morphology, mitochondrial density was quantified using Mean Grey Value on an 
inverted-color image (ImageJ). 25-30 total representative mitochondria were assessed 
per treatment group from 3 or more eyes. 
 
 
Protein Expression in the RPE/Choroid  
Eyes were enucleated and the cornea removed in order to detach the lens and retina. 
The RPE/choroid complex was scraped from the sclera carefully using a scalpel and 
collected in cold PBS, homogenized and stored at -80oC. Homogenate was suspended 
in loading buffer and subjected to a 4-15% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis. The resolved proteins were transferred to a polyvinylidene fluoride 
membrane. After electroblotting, the membrane was incubated overnight with one of 
the following antibodies: anti-VEGF (1:250) (Millipore, Billerica, MA), anti-TNFα 
(1:250) (Abcam, Cambridge, MA), anti-CCL2/MCP-1 (1:2000) (Abcam, Cambridge, 
MA), anti-eNOS (1:500) (Abcam, Cambridge, MA), anti-AMPK (1:500) (R&D 
Systems, Minneapolis, MN), or anti-β-actin (1:5000) (Santa Cruz, Dallas, TX). 
Membranes were further incubated for 1 hour with their respective HRP-conjugated 
antibodies. Protein bands were detected with an enhanced chemiluminescence 
detection system (Cell Signaling, Danvers, MA). Bands were evaluated for integrated 
density values with ImageJ software. AMPK [p-172] levels were quantified using the 
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AMPK [pT172] ELISA Kit (Life Technologies, Carlsbad, CA) according to 
manufacturer’s protocol. 
 
Statistical Analyses 
All data are presented as mean ± S.E. One-way analysis of variance (ANOVA) was 
used for group comparisons. Post-hoc multiple comparisons were performed using 
Tukey’s correction methods (GraphPad Software, Inc., San Diego, CA). Statistical 
comparisons were considered significantly different at P < 0.05. 
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RESULTS 
 
 
Longitudinal changes in spatial visual function during high fat feeding 
There was no change in SF threshold in ND mice over the course of this study, from 4 
weeks through 32 weeks of age (Fig. 1A). A decrease in SF threshold was apparent 
after just 4 weeks of HFD, even before the administration of STZ. Spatial vision 
deteriorated markedly by 12 weeks and continued to decline throughout the study 
period, reaching 0.25 c/d by 32 weeks (Fig. 1A). Daily topical application of SS-31 
starting at 12 weeks arrested the decline in SF in HFD+STZ mice, and gradually 
restored visual function to normal levels by 20 weeks.  
 
Basal metabolic parameters during high fat feeding 
Body weight in the HFD+STZ mice (n=6) was not different from ND mice (n=5) at 12 
weeks (29.5 ± 0.07 vs 25.2 ± 0.29 g), at the time when there was significant decline in 
visual function. Body weight was significantly higher in HFD+STZ mice by 30 weeks 
(59.4 ± 0.15 vs 33.0 ± 0.23 g; P < 0.001) (Fig. 1B). Daily topical application of SS-31 
starting at 12 weeks had no effect on body weight in HFD+STZ mice at 30 weeks 
(59.1 ± 0.22 g vs 59.4 ± 0.15 g; n=6) (Fig. 1B). Non-fasted blood glucose was slightly 
elevated in HFD+STZ mice at 12 weeks (202 ± 1.7 vs 184 ± 0.5 mg/dl), but was 
significantly elevated at 30 weeks (291 ± 2.0 mg/dl vs 190 ± 5.3; P < 0.001) (Fig. 1C).  
Daily topical application of SS-31 starting at 12 weeks had no effect on blood glucose 
in HFD+STZ mice at 30 weeks (287.5 ± 5.2 mg/dl). Glucose clearance, as determined 
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by GTT, was impaired by 12 weeks and persisted through 30 weeks, and was 
unaffected by SS-31 (Fig. 1D and E). 
 
Disruption of RPE morphology during high fat feeding The delicate laminar 
architecture of the retina was relatively unaltered in HFD+STZ mice when compared 
to ND mice at 32 weeks of age (Fig. 2A). Higher magnification revealed disruption of 
the single cell layer of the RPE in HFD+STZ mice (Fig. 2B, arrows). Examination of 
the RPE layer by TEM revealed occasional degenerating cells with loss of cell 
contents (Fig. 2C). The RPE layer was intact in HFD+STZ mice that received daily 
SS-31 treatment starting at 12 weeks (Fig. 2A-C). Flatmounts of the RPE layer was 
stained with phalloidin (F-actin) to visualize the hexagonal lattice. The RPE of ND 
mice showed relative homogeneity with respect to cell size (Fig. 2D and E). 
Significantly more variability was seen in the HFD+STZ group, with much larger and 
much smaller cells present. SS-31-treatment prevented the heterogeneity in cell size 
seen in the HFD+STZ group, maintaining a size distribution similar to the vehicle-
treated mice (Fig. 2D and E). 
 
RPE mitochondrial and cellular structure during high fat feeding 
ND mice exhibited normal RPE morphology and ultrastructural histology at 32 weeks 
of age (Fig. 3A). The RPE layer maintained continuous cell-cell contact (white arrow) 
with numerous intricate basolateral infoldings (*). The cytoplasm was filled with 
pigmented granules (PG) and there was no sign of endoplasmic reticulum (ER) stress. 
Mitochondria (M) are elongated and clustered along the basal membrane infoldings 
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and along cell-cell junctions. In contrast, RPE cells from HFD+STZ mice exhibited an 
interrupted RPE barrier with breaks and spaces between cells (black arrow) (Fig.3C 
and 3D). Basolateral infoldings were edematous and swollen (**), and were 
occasionally filled with membrane-bound vesicles. ER stress was apparent, as were 
rounded and swollen mitochondria (M) that were depleted of cristae membranes (Fig. 
3C). SS-31-treated HFD+STZ mice displayed RPE morphology similar to ND 
animals, with extensive basolateral infoldings, no edema, tight cell junctions (white 
arrow), elongated mitochondria (M), and no ER stress (Fig. 3D). Higher magnification 
of the RPE revealed notable differences in mitochondria structure among the three 
groups (Fig. 3E). Mice fed ND displayed elongated mitochondria densely packed with 
cristae membranes and electron-dense matrix. RPE from HFD+STZ mice featured 
swollen mitochondria with a rounded shape, with few cristae and an electron-lucent 
matrix. In contrast, SS-31-treated HFD+STZ mice exhibited mitochondrial 
morphology similar to ND mice. Mitochondrial density was significantly reduced in 
the HFD+STZ mitochondria, but there was no difference between HFD+STZ mice 
treated with SS-31 and ND mitochondria (Fig. 3F).  
 
Choroidal neovascular tufts are seen with high fat feeding 
Isolectin IB4 selectively labels endothelial cell glycocalyx, but the highly pigmented 
RPE and choroid of C57BL/6 mouse eyes normally prevent visualization of the 
choroidal capillaries.  Notably, punctated staining was seen throughout the eye cup in 
HFD+STZ mice but not in ND or HFD+STZ mice treated with SS-31 (Fig. 4A). 
Higher magnification revealed these isolectin-stained cells to be single cells with 
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processes radiating outwards from a central tuft (Fig. 4B). Closer inspection with z-
stack confocal microscopy revealed these tufts to be between the apical face of the 
RPE lattice and the photoreceptors of the neural retina (Fig. 4C). These neovascular 
tufts were not seen in ND mice or HFD-STZ mice treated with SS-31 (Fig. 4D).  
 
Characterization of Fundus and Retinal Vasculature during high fat feeding 
Fundus photography showed no difference in gross morphology between HFD+STZ 
mice and ND mice (Fig.5A). The retina appeared healthy in all animals with no signs 
of hypoxia or vascular abnormalities.  Fluorescein angiography also showed no 
notable differences between the inner retinal vasculature among the three groups, with 
all animals lacking obvious signs of occlusion or leakage (Fig. 5B and C). 
 
High fat feeding leads to loss of AMPK activity 
There was a significant decrease in phosphorylated AMPK (pAMPKa) in HFD+STZ 
mice at 32 weeks (Fig. 6A). Treatment with SS-31 starting at 12 weeks partially 
restored pAMPKa in HFD+STZ mice (Fig. 6A). This reduction in pAMPKa reflects a 
reduction in AMPK activation rather than a decline in protein levels (Fig. 6B).  
 
Upregulation of hypoxia and inflammatory markers in the retina during high fat 
feeding 
Although VEGF is normally expressed in the RPE/choroid complex in ND mice, it 
was significantly upregulated in the HFD+STZ retinas (Fig. 6C). Treatment with SS-
31 starting at 12 weeks prevented this upregulation of VEGF in HFD+STZ mice (Fig. 
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6C). The upregulation of VEGF is likely in response to hypoxia and indicates retinal 
ischemia during high fat feeding. Endothelial nitric oxide synthase (eNOS) is 
responsible for the production of nitric oxide (NO), a critical vasodilatory element that 
was significantly downregulated in HFD+STZ mice at 32 weeks, suggesting that high 
fat feeding dramatically compromises choroidal blood flow. This down-regulation of 
eNOS in HFD+STZ mice was completely prevented by treatment with SS-31 (Fig. 
6D). Retinal inflammation is a prominent component of DR, and we find a significant 
increase in tumor necrosis factor-α (TNFα) and monocyte chemotactic protein 1 
(MCP1) (also known as chemokine ligand 2 (CCL2)) in the choroid/RPE in HFD mice 
(Fig. 6E and 6F). Treatment with SS-31 completely abolished the upregulation of 
these proinflammatory markers in the RPE/choroid, suggesting that SS-31 has an anti-
inflammatory action in the retina. 
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DISCUSSION 
 
 
Our recent study was the first longitudinal study documenting the decline in SF 
threshold starting after just 4 weeks of HFD in mice (10). In this study, we show the 
lack of any change in the inner retinal vasculature even after 28 weeks of HFD. 
Instead, this early visual dysfunction is correlated with specific disruption of the RPE 
and choroidal neovasculature. Our results support a model whereby HFD induces 
choroidal endothelial cell dysfunction and downregulation of eNOS that results in 
decreased choroidal blood flow (Fig. 7). As the choroidal vasculature accounts for 
80% of retinal blood flow, any reduction in choroidal blood flow greatly reduces 
blood supply to the RPE and decreases mitochondrial ATP production. Bioenergetics 
failure in the RPE compromises its myriad of ATP-dependent functions that result in 
photoreceptor dysfunction, retinal edema, inflammation and neovascularization (Fig. 
7).  Our study is the first to demonstrate that protection of the choroidal vasculature 
and RPE bioenergetics can arrest and reverse the visual decline seen in early metabolic 
syndrome. These findings are novel and have significant translational relevance. The 
treatment of diabetic vision loss is currently limited to VEGF inhibitors in the late 
stages of the disease. These anti-VEGF therapies are expensive, complicated to 
administer, marginally successful, and fail to mitigate the underlying basis of the 
disease.  SS-31 represents a novel approach to the treatment of DR. First, SS-31 acts 
directly on the mitochondrial ETC to improve retinal bioenergetics (16; 17). Second, 
SS-31 can reverse diet-induced visual dysfunction without lowering body weight or 
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blood glucose. Third, SS-31 is highly effective in protecting endothelial and epithelial 
cells in ischemic conditions (22-24). Fourth, SS-31 can be easily administered as an 
eye drop, it has a rapid onset of action, and an excellent safety profile (16; 17; 25). 
Based on this research, topical SS-31 (OcuviaTM) has just entered Phase 2 clinical trial 
for diabetic macula edema (NCT02314299).  
 
While hyperglycemia is often thought to be the driving force behind diabetic 
complications, our results show that decline in spatial visual function begins before 
any increase in blood glucose. Impaired glucose clearance at 12 weeks suggests that 
insulin resistance, rather than hyperglycemia, might be responsible for the initial 
visual decline. Extensive evidence support the development of insulin resistance after 
just a few weeks of high fat feeding, as demonstrated by elevated plasma insulin 
levels, insulin-stimulated glucose metabolism, and euglycemic-hyperinsulinemic 
clamp studies (26-28). Blunted Akt phosphorylation has been shown in retina and 
other organs (26; 27; 29). Thus impaired insulin sensitivity can develop rapidly with 
relatively short interval of HFD. The vascular endothelium is an important insulin 
target, and disruption of insulin signaling reduces the expression of endothelial nitric 
oxide synthase (eNOS) and inhibits nitric oxide (NO) production, resulting in 
endothelial dysfunction and ischemia (30-32). In this study, downregulation of eNOS 
in the RPE/choroid confirms retinal insulin resistance and endothelial dysfunction.  
 
Retinal ischemia/hypoxia triggers the upregulation of VEGF and abnormal 
angiogenesis (33). Here we demonstrate a very early manifestation of this 
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neovascularization process, small neovascular tufts that are visible above the RPE. 
Similar early-stage neovascular tufts have been reported in rats fed a high-fructose diet 
(8). Additionally, microaneurysms have been seen in rabbits on high-fat and high-
sucrose diet while gross retinal morphology remained intact (34). High fat feeding 
further triggers retinal inflammation (35; 36), and we found significant elevation of 
TNFα and MCP-1/CCL2 expression in HFD+STZ retinas, consistent with retinal 
hypoxia. TNFα is required for late breakdown of the BRB in diabetic mice (37), and 
MCP-1 plays an important role in recruiting monocytes and macrophages to the eye in 
DR (38).  
 
Insulin resistance is especially problematic for the choroidal vasculature where 
constitutive insulin signaling is responsible for glucose uptake required for the 
metabolically active retina (39; 40). The RPE is highly dependent on mitochondrial 
ATP generation to support its numerous functions that are essential for the action and 
survival of photoreceptors (15). Even moderately reduced ATP levels greatly reduce 
phagocytic activity of human RPE cells (41). Our results show that even short-term 
high fat feeding cause mitochondrial swelling and loss of cristae membranes in the 
RPE, leading to insufficient ATP. Cellular edema, disruption of basal membrane 
infoldings, and loss of cell-cell contact, are typical signs of ATP depletion (42). 
Similar mitochondrial swelling led to apoptosis in retinal neurons of early diabetic rats 
(43). High fat feeding for 3 months was shown to decrease both outer and inner retina 
thickness and increase apoptosis in rats, indicating modest retinal degeneration (28). 
The change in RPE morphometrics with the appearance of some large cells with more 
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than 6 sides suggests that there has been some cell loss and surrounding cells are 
enlarged in an attempt to protect the BRB (44). Sporadic breakdown in the RPE sheet 
may allow the choroidal neovascular tufts to migrate above the RPE (45).  
 
SS-31 is the first pharmacological agent that can arrest visual decline, and even 
restore visual function, in high fat feeding, despite having no effect on body weight, 
blood glucose, or systemic glucose clearance. We previously reported that HFD and 
insulin resistance in skeletal muscles is associated with increased mitochondrial H2O2 
production, and by reducing mitochondrial ROS, SS-31 prevented insulin resistance in 
skeletal muscles (27). In this study, SS-31 was initiated after onset of insulin 
resistance and visual decline, but it was able to normalize the expression of eNOS and 
VEGF in the RPE/choroid, suggesting that SS-31 can improve insulin sensitivity in 
retinal endothelial cells and preserve choroidal blood flow (Fig. 7). By preventing 
retinal hypoxia, choroidal neovascularization and inflammation were also prevented. 
In addition, SS-31 is known to minimize ischemic injury by protecting mitochondria 
cristae structure and maximizing ATP production under low substrate conditions in 
endothelial and epithelial cells (24; 42; 46). Here, mitochondria in the RPE appeared 
normal during high fat feeding, and the ATP-dependent processes of the RPE 
monolayer were maintained (42; 46). Thus, SS-31 also helps the RPE tolerate retinal 
ischemia better and maintain cellular structure and function (Fig. 7). Later when blood 
glucose becomes elevated, SS-31 may, in addition, protect against the detrimental 
effects of high glucose on retinal endothelial cells. This is supported by a prior study 
showing that SS-31 can stabilize mitochondrial potential, reduce ROS production, and 
 59 
prevent cytochrome c release in human retinal endothelial cells subjected to high 
glucose conditions (47). Thus SS-31 provides a novel therapeutic approach for 
minimizing end-organ damage in diabetes by promoting mitochondrial bioenergetics 
rather than reducing blood glucose or increasing insulin sensitivity. AMPK, the fuel-
sensing enzyme activated by low ATP levels, is known to be dysregulated in insulin 
resistance and diabetes, and strategies that activate AMPK can be helpful for these 
conditions (48). Interestingly, resveratrol normalized AMPK activity in retinas of 
diabetic mice and prevented retinal inflammation and VEGF upregulation without 
reducing blood glucose (49). Metformin, the diabetic drug that modestly improves 
insulin sensitivity, was reported to act as an AMPK activator, but it does so by 
inhibiting complex I of the ETC (50). AMPK activity was significantly down-
regulated in the HFD+STZ mice, and treatment with SS-31 significantly improved 
phosphorylated AMPK levels in the retina. Unlike metformin, SS-31 promotes 
efficiency of the ETC to increase ATP production and reduce ROS emission (17).  
Restoration of the bioenergetic capacity of the retina may play a role beyond diabetic 
retinopathy. Impairment of the RPE and choroidal neovascularization are also 
hallmarks of age-related macula degeneration, and our results suggest that SS-31 may 
be beneficial for this disease.  
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FIGURE LEGENDS 
 
 
Fig. 1.  Longitudinal changes in spatial frequency threshold during high fat feeding.  
A. Spatial frequency stays constant in ND mice, but declines progressive in HFD+STZ 
animals starting at 8 weeks. SS-31 treatment starting at 12 weeks reverses the decline 
and restores SF threshold in HFD+STZ mice. B. Body weight showed no difference at 
12 weeks, but was significantly elevated in the HFD+STZ animals at 30 weeks. C. 
Resting blood glucose was slightly elevated in HFD+STZ mice at 12 weeks, but was 
significantly increased at 30 weeks. D & E. Glucose clearance was significantly 
impaired in HFD+STZ at both 12 and 30 weeks. Daily treatment with topical SS-31 
had no effect on body weight, blood glucose or glucose clearance in HFD+STZ mice.  
 
Fig. 2.  Disruption of RPE morphology during high fat feeding.  A. Laminar 
architecture of the retina, with ganglion layer at top and choroid at bottom (x200). No 
notable disruptions to the laemellar architecture are obvious. B. The RPE single cell 
layer is disrupted in HFD+STZ mice (arrows) (x400). SS-31 treatment preserved the 
continuity of the RPE monolayer. C. Electron micrographs show occasional 
degenerating RPE cell in HFD+STZ mice. D. Representative flat mount images of the 
RPE with phalloidin (green) depicting the cell lattice. E. RPE cell size exhibited little 
variation in ND mice, but was much more variable in HFD+STZ animals. SS-31-
treated mice showed distribution similar to ND mice.  
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Fig. 3. Electron micrographs of the RPE.  A. RPE from ND mice demonstrate intricate 
basal membrane infoldings (*), tight cell-cell contact (white arrow), elongated cristae-
dense mitochondria (M), and pigment granules (PG).  B & C. RPE from HFD+STZ 
mice exhibit separation of cell-cell contact (black arrow), swollen mitochondria (M) 
and either edematous basal membrane infoldings or a total loss of infoldings.  D. RPE 
from HFD+STZ mice treated with SS-31 have tight cell-cell contact (white arrow), 
elongated cristae-dense mitochondria (M), and proper membrane infoldings (*).  
E. Representative mitochondria from ND, HFD+STZ, and HFD+STZ mice treated 
with SS-31. F. Quantification of mitochondrial density. *** P < 0.001. 
 
Fig. 4.  Morphology of RPE and choroidal vasculature.  A. Flat-mounted retinas 
labeled with phalloidin (green, depicting the hexagonal lattice of the RPE) and 
isolectin IB4 (red, depicting endothelial glycocalyx) around the optic nerve. 
Neovascular tufts are numerous in the HFD+STZ mice (see as red dots), but not in 
mice treated with SS-31. B & C. Higher magnification reveals neovascular tufts with 
spider-like processes in HFD+STZ mice. Z-stack shows the tufts sitting directly above 
the apical side of the RPE layer inside the retina, but under the photoreceptor outer 
segments. Images taken with the support of Guillermo Lehmann Mántaras, M.D., 
Ph.D. D. Quantification of neovascular tufts.  
 
Fig. 5.  A. Representative fundus photographs showing no difference in gross 
morphology with high fat feeding. The retina appeared healthy with no signs of 
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no notable differences in the inner retinal vasculature with high fat feeding, with no 
obvious signs of occlusion or leakage. C. Magnification of inset shown in B. 
 
Fig. 6.  Protein expression in the RPE/choroid.  A. pAMPKα.  B. AMPKa. C. VEGF.  
D. eNOS. E. TNFα.  F. MCP-1 or CCL2. * P < 0.05; ** P < 0.01; *** P < 0.001. 
 
Fig. 7.  Schematic summarizing the progression from early endothelial cell damage in 
the choroid and RPE bioenergetics failure to retinal edema, inflammation, and 
choroidal neovascularization in DR.  SS-31 protects choroidal endothelial cells and 
protects choroidal blood flow, thereby preventing injury to the RPE, retinal 
inflammation and choroidal neovascularization. In addition, SS-31 protects the RPE 
from ischemic injury.   
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Fig. 1.  Longitudinal changes in spatial frequency threshold during high fat feeding.   
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Fig. 2.  Disruption of RPE morphology during high fat feeding. 
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Fig. 3. Electron micrographs of the RPE.   
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Fig. 4.  Morphology of RPE and choroidal vasculature.   
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Fig. 5.  A. Representative fundus photographs. 
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Fig. 6.  Protein expression in the RPE/choroid.  
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Fig. 7.  Summary schematic. 
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ABSTRACT 
 
Diabetic retinopathy is characterized by progressive vision loss and the advancement 
of retinal micoraneurysms, edema, and angiogenesis. Unfortunately, managing 
glycemia or targeting vascular complications with anti-vascular endothelial growth 
factor agents has shown only limited efficacy in treating the deterioration of vision in 
diabetic retinopathy. In light of growing evidence that mitochondrial dysfunction is an 
independent pathophysiology of diabetes and diabetic retinopathy, we investigated 
whether selectively targeting and improving mitochondrial dysfunction is a viable 
treatment for visual decline in diabetes. Measures of spatial visual behavior, blood 
glucose, bodyweight, and optical clarity were made in mouse models of diabetes. 
Treatment groups were administered MTP-131, a water-soluble tetrapeptide that 
selectively targets mitochondrial cardiolipin and promotes efficient electron transfer, 
either systemically or in eye drops. Progressive visual decline emerged in untreated 
animals before the overt symptoms of metabolic and ophthalmic abnormalities were 
manifest, but with time, visual dysfunction was accompanied by compromised glucose 
clearance, and elevated blood glucose and bodyweight. MTP-131 treatment reversed 
the visual decline without improving glycemic control or reducing bodyweight. These 
data provide evidence that visuomotor decline is an early complication of diabetes. 
They also indicate that selectively treating mitochondrial dysfunction with MTP-131 
has the potential to remediate the visual dysfunction, and complement existing 
treatments for diabetic retinopathy.  
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INTRODUCTION 
 
Diabetic retinopathy is a leading cause of progressive vision loss and blindness. It 
is characterized by occlusion and leakage of retinal vessels, which leads to macular 
edema in its non-proliferative phase, and angiogenesis and retinal detachment in its 
proliferative phase. Whereas vascular endothelial growth factor expression is 
necessary for the angiogenesis (Stefanini et al., 2014), treatment with anti- vascular 
endothelial growth factor agents is able to improve visual function in <30% of 
patients. Likewise, therapies aimed at managing the symptoms of metabolic 
dysfunction have shown limited efficacy in slowing the progression of diabetic 
retinopathy; diabetic complications develop in ~20% of patients under strict glycemic 
or blood-pressure control (Antonetti et al., 2012). Thus, earlier detection of risk for 
diabetes and diabetic retinopathy, and intervention with novel therapeutics before 
irreversible retinal damage occurs, has great potential to improve treatment. 
There is growing recognition that retinal dysfunction (Barber et al., 2005; Ly et al., 
2011; Martin et al., 2004; Murakami and Yoshimura, 2013; van Dijk et al., 2009) and 
impaired visual behavior is present in human diabetics and animal models before 
retinal vascular changes are evident (Akimov and Rentería, 2012; Aung et al., 2013; 
Hardy et al., 1992; Jackson et al., 2012; Kirwin et al., 2011). Thus, the identification 
of visual dysfunction early in the course of diabetes may provide an advanced 
opportunity for therapeutic intervention. A promising candidate for early intervention 
in diabetic retinopathy is the remediation of mitochondrial dysfunction. Diabetic 
complications in the non-proliferative phase of diabetic retinopathy are associated 
with metabolic pathways that are up-regulated by sustained hyperglycemia: increased 
polyol pathway flux, increased formation of advanced glycation end products and their 
receptors, activation of protein kinase C, and increased hexosamine pathway flux 
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(Forbes and Cooper, 2013). It has been proposed that the pathways are linked by the 
mitochondrial production of reactive oxygen species resulting from increased 
metabolic flux through the electron transport chain. This is supported by evidence that 
normalizing mitochondrial superoxide production can mitigate hyperglycemic damage 
(Brownlee, 2001; Nishikawa et al., 2000).  
Indeed, mitochondria are simultaneously a major source of intracellular reactive 
oxygen species and the target of oxidative damage, and evidence of mitochondrial 
oxidative stress is present when histopathological abnormalities arise in diabetic 
retinopathy (Du et al., 2003; Kowluru and Zhong, 2011). Altered mitochondrial 
structure, including swelling and loss of cristae, the accumulation of defects in 
mitochondrial DNA, and a reduction of transport proteins (Kowluru and Zhong, 2011; 
Madsen-Bouterse et al., 2010b; Santos and Kowluru, 2013) which may be independent 
of hyperglycemia (Zhong and Kowluru, 2011), have also been reported. In addition, 
impairment of retinal pigment epithelium mitochondria is associated with increased 
oxidative stress, reduced ATP, and compromised autophagic and phagocytic capacities 
(He et al., 2010; Kanwar et al., 2007; Li et al., 2014; Madsen-Bouterse et al., 2010a). 
Taken together, these data indicate that apoptotic stress in the retina has the capacity to 
induce the hallmark microvascular injury of diabetic retinopathy, and that improving 
mitochondrial function may be an effective treatment. 
Whereas antioxidants have shown promise in preclinical studies as a therapy for 
diabetic retinopathy (Huang et al., 2013; Nawaz et al., 2013; Xie et al., 2008), they 
have not been effective in clinical trials; possibly due to their inability to penetrate 
mitochondria. This problem can be overcome with the use of MTP-131 (also known as 
SS-31), a water-soluble mitochondria-targeting peptide that attenuates mitochondrial 
reactive oxygen species production and cytochrome c release (Huang et al., 2013; Li et 
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al., 2011; Szeto and Birk, 2014; Zhao et al., 2004). We thus tested the hypothesis here 
that MTP-131 can remediate visual impairment in mouse models of diabetes.   
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RESULTS 
 
Characterization of Diabetic Mouse Models  
Type-1 diabetes is an autoimmune disease that leads to loss of insulin-producing 
beta cells in the pancreas, which is often modeled in animal studies with injections of 
streptozotocin (STZ). We administered STZ to C57BL/6 mice fed a normal diet (ND) 
for 5 days at 8 weeks of age (ND+STZ). Type-2 diabetes is characterized by insulin 
resistance and the inability of β-cells to up-regulate their insulin production. For 
modeling this, mice were fed a diabetic diet (DD) high in fat and carbohydrates from 4 
weeks of age, and a third group received both DD and STZ (DD+STZ). Control mice 
were fed a ND throughout the study.  
Elevated resting blood glucose (non-fasted) was present in each diabetic model by 
15 weeks, which was sustained at 32 weeks (Fig. 1A). Evidence of insulin resistance 
was also present in the results of a glucose tolerance test administered at 12 (Fig. 1B) 
and 30 weeks (Fig. 1C), with DD groups showing the greatest impairment. Elevated 
bodyweight emerged by 15 weeks in groups fed a DD, and by 32 weeks, mice in the 
DD groups were two-fold heavier than mice fed a ND (Fig. 1D, ~56g vs ~29g).  
 
Progressive Decline of Visual Function in Diabetic Mouse Models 
Spatial frequency (SF) and contrast thresholds for optokinetic tracking were 
measured through each eye once/week from 3-32 weeks, using a virtual optokinetic 
system (Prusky et al., 2004). SF thresholds near 0.39 cycles/degree (c/d) were 
measured in ND mice (Fig. 2A) up to 32 weeks; performance comparable to 
previously-published values (Prusky et al., 2004; Prusky et al., 2006). Loss-of-
function emerged by 12 weeks in ND+STZ mice, which by 32 weeks, was reduced by 
17%. Visual dysfunction emerged earlier (at 9 weeks) and declined more (29%) in DD 
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mice. In DD+STZ mice, visual dysfunction emerged the earliest (at 8 weeks), and 
declined the most (38%), by 32 weeks.  
We have previously defined the luminance conditions in the virtual optokinetic 
system that are able isolate cone- and rod-only function (Alam et al., 2015; Altimus et 
al., 2010), and as such, the lighting conditions used to record the thresholds in Fig. 2A 
were selective for cone-mediated function. In order to measure rod-mediated function 
in the same animals, we configured the virtual optokinetic system to record rod-driven 
thresholds in low light conditions. Fig. 2B is a comparison of cone- and rod-selective 
function at 28 weeks. Whereas cone function was reduced by 16% in ND+ STZ mice, 
27% in DD mice, and 36% in DD +STZ mice, rod function was proportionally less 
affected; ND+ STZ = 3%; DD = 10%, and DD +STZ = 18%. Thus, the loss of visual 
function in the diabetic models was primarily due to compromised cone-mediated 
responses.  
Measures of CS also revealed evidence of visual decline that was graded by group. 
Adult-like CS (Douglas et al., 2005; Prusky et al., 2004) was present in ND mice at 4, 
12, and 32 weeks (Fig. 2C). CS in ND+STZ mice (Fig. 2D) was normal at 4 and 12 
weeks, but was slightly reduced by 32 weeks at SFs above 0.06 c/d. CS in DD mice 
was marginally lower at high SFs between 4 and 12 weeks, and by 32 weeks, was 
reduced at all SFs above 0.03 c/d (Fig. 2E). DD+STZ mice showed loss of function 
from 4-12 weeks comparable to DD mice, but showed a greater decline by 32 weeks 
(Fig. 2F).  
 
MTP-131 Treatment Reversed Visual Decline in Diabetic Mouse Models 
Treatment groups were injected with MTP-131 (1 mg/kg), (Veh; 0.9% saline), 
subcutaneously once/day from 12 weeks; an age by which evidence of visuomotor 
dysfunction had developed in each of the diabetic models (i.e. Fig. 2). The treatment 
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did not alter the level of non-fasted resting blood glucose (Fig. 3A), and did not 
change the rate of glucose clearance measured at 30 weeks (compared to Veh group; 
Fig. 3B). Likewise, the treatment did not correct the elevated bodyweight of the DD 
groups (Fig. 3C). Improvement of visual function, however, was present in each of the 
diabetic groups.  Fig. 4A shows that improvement of the SF threshold for opto-kinetic 
tracking was present in DD+STZ mice 1 week after treatment, within 4 weeks in DD 
mice, and within 6 weeks in ND+STZ mice. Improvement continued thereafter in all 
groups until thresholds were restored to normal values by 24 weeks in DD+STZ mice, 
by 25 weeks in ND+STZ mice, and by 31 weeks in DD mice. MTP-131 treatment did 
not alter function in the control (ND) group. Cone-and rod selective dysfunction in the 
MTP-131 treated mice were both fully reversed in ND+STZ and DD+STZ groups, and 
substantially remediated in the DD group (Fig. 4B; compare with 28 weeks in Fig 2B). 
MTP-131 treatment improved CS in a similar manner; MTP-131 did not affect CS in 
ND mice (Fig. 4C), but it restored thresholds to near-normal values in ND+STZ (Fig. 
4D), in DD (Fig. 4E), and DD+STZ mice (Fig. 4F). Ophthalmic examinations of mice 
presented in Figs. 3 & 4 revealed only sporadic ocular abnormalities, none of which 
were related to group or treatment. All animals were assessed at 12 weeks of age, prior 
to starting any treatment, and at 32 weeks prior to euthanasia, using a modification of 
the MacDonald-Shadduck Scoring System described elsewhere (Altmann et al., 2010). 
Ophthalmic examinations identified three animals with abnormal visual thresholds at 
12 weeks, in the form of dense corneal infiltrates or central opacities, likely due to 
grooming or fighting. The mice were removed from the study. Two left eyes and two 
right eyes showed small punctate corneal opacities (less than 25% corneal 
involvement (score=1), either in the inferior or nasal region of 4 animals prior to 12 
weeks of age, but that animals remained in the study and were randomly assigned into 
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groups. Ophthalmic examinations were performed again at 32 weeks of age, and no 
animals were identified with ocular problems.  
 
Efficacy of MTP-131 Applied Via Eye Drops  
We hypothesized that the benefit of systemic MTP-131 treatment was related to its 
action on the retina, since MTP-131 did not correct weight gain or high blood glucose. 
In an effort to deliver MTP-131 to the eye, we investigated whether eye drop 
application of the peptide would also treat diabetic visual dysfunction. Fig. 5A, B and 
C shows that resting blood glucose and body weight measures were unaffected by 
MTP-131 or placebo (Veh) eye drop application. In Fig. 5C, Veh-treated mice 
exhibited a SF threshold decline comparable to that with systemic Veh treatment (Fig. 
2A, magenta line). However, decline in the MTP-131 eye drop-treated group was 
reversed after 1 week of treatment, and normal function was reinstated by 20 weeks- 4 
weeks earlier than with systemic MTP-131 treatment in the same model.  
In a separate cohort of mice, we investigated whether the timing and rate of visual 
recovery following the application of MTP-131 was dose-dependent (Fig. 5D). 
Improved function was observed within one week of treatment with 30 mg/ml, and 
within 5 weeks with 10 mg/ml. 1 mg/ml treatment did not lead to improvement. As 
with systemic MTP-131 treatment, the restoration of function with eye drop 
application of MTP-131 was independent of overt changes in the quality of the optical 
axis (data not shown). 
 
MTP-131 Reversed More Severe Visual Dysfunction  
To determine whether MTP-131 application was able to remediate more 
pronounced visual dysfunction than that at 12 weeks (i.e. Fig. 5), eye drop treatment 
with MTP-131 (30 mg/ml) was initiated in a group of DD+STZ mice at 34 weeks; an 
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age at which the SF threshold in untreated animals was reduced by ~50% (Fig. 6C). 
As in previous experiments, MTP-131 treatment had no effect on resting blood 
glucose (Fig. 6A) or body weight (Fig. 6B). Unlike the effect on visual function with 
treatment from 12 weeks, which showed a beneficial effect within 1 week (Fig. 5C), 
visual function continued to decline for 4 weeks after MTP-131 treatment in the 
group. At 5 weeks, however, visual decline was halted, followed by recovery at a rate 
similar to that with treatment from 12 weeks, reaching ~75% of normal by 52 weeks 
(Fig. 6C). As stipulated by our animal protocol, the study was terminated at 52 weeks, 
and thus, it is not known whether continued treatment would have led to more 
improvement. However, the rate of recovery appeared to slow after 48 weeks, likely 
indicating that complete recovery would not be achieved with more time. Whereas CS 
was measured in all of the eye drop studies, it changed in concert with measures of SF 
thresholds, and thus, the data is not presented here.  
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DISCUSSION 
 
This study, which unfolded over the course of 2 years and utilized > 150 mice, is 
the most comprehensive examination to date of visual decline, and restoration with 
treatment, in rodent models of diabetes. It established a time course of the relationship 
between the emergence of metabolic dysfunction and visual decline in three diabetic 
models in the same mouse strain, it illuminated a role for mitochondrial dysfunction in 
the pathogenesis of diabetic visual complications, and it demonstrated a clinically-
feasible approach to treating it.  
We used a repeated low-dose STZ protocol to model type-1 diabetes, rather than 
the typical single high dose STZ protocol, to reduce the off-target toxic effects of STZ 
(Hayashi et al., 2006; Like and Rossini, 1976). This resulted in only a moderate 
increase in fed blood glucose (Hayashi et al., 2006; Leiter, 1982) and slightly 
abnormal glucose clearance, which may better model type-1 diabetes. Feeding a diet 
high in fat and carbohydrates was used to model type-2 diabetes, which led to an 
increase in body weight, abnormal glucose clearance, and mild hyperglycemia. 
Although we did not measure insulin in this study, an increase in plasma insulin has 
previously been reported in diet-induced models of diabetes (Park et al., 2005; Surwit 
et al., 1988). For example, a decrease in insulin-stimulated glucose uptake in the heart 
has been reported within 1.5 weeks of initiating a high fat diet in young C57BL/6 
mice, which was reduced by ~90% after 20 weeks (Park et al., 2005). In addition, 
plasma insulin was elevated within 2 weeks in young mice fed a high fat diet, and 
remained elevated for up to 52 weeks (Park et al., 2005; Surwit et al., 1988; Winzell 
and Ahrén, 2004). Thus, the DD model enabled the ability to study the effect of 
insulin resistance on visual function. Indeed, the elevated blood glucose in DD mice 
most likely resulted from reduced glucose uptake by skeletal muscles and adipose 
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tissue, due to loss of insulin signaling (Winzell and Ahrén, 2004). A group that 
combined DD with STZ treatment provided a model of advanced type-2 diabetes, 
which is characterized by defects in insulin secretion and insulin resistance.  
A decline of visuomotor function was detected in each experimental model before 
changes in resting blood glucose emerged- a common clinical indicator of 
susceptibility to diabetes. The onset of visual decline was most rapid in the DD+STZ 
group, and slowest in the ND+STZ group, suggesting that insulin resistance may have 
an early negative effect on visual function. Insulin receptors are expressed on both 
vascular and neural cells of the retina (Haskell et al., 1984), and are able to 
autophosphorylate and activate downstream kinases, as in other insulin-sensitive 
tissues (Reiter et al., 2003). Rats administered STZ have shown reduced insulin 
receptor signaling in the retina, especially in retinal endothelial cells, which may 
contribute to the early progression of diabetic retinopathy (Aizu et al., 2002; Fort et 
al., 2011; Kondo and Kahn, 2004; Reiter et al., 2003).  
The study was designed such that daily MTP-131 treatment began 4 weeks after 
STZ treatment, or 8 weeks after the initiation of a DD. Since visual decline only began 
4 weeks after STZ, MTP-131 treatment appeared to both reverse further decline, and 
prevent sustained visual dysfunction. MTP-131 treatment was also able to reverse 
more pronounced visual dysfunction in the DD group, but the time to full recovery 
was shortened. Unexpectedly, even though the DD+STZ mice had the most dramatic 
rate of visual decline; they had the most rapid response to MTP-131 treatment, 
showing improvement within one week of MTP-131 administration and full recovery 
after 12 weeks. The lack of effect of MTP-131 on blood glucose and body weight is in 
keeping with previous reports in STZ-administered rats (Huang et al., 2013). The more 
rapid onset of visual decline, and the slower treatment response in the DD group is 
also consistent with insulin resistance as a cause of diabetic visual dysfunction. Since 
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the addition of STZ has been shown to reduce diet-induced insulin resistance in 
C57BL/6 mice (Ning et al., 2011), this may account for the more rapid MTP-131 
treatment effect in the DD+STZ group. 
MTP-131 is a mitochondria-targeting peptide known to protect the structure of 
cristae and prevent mitochondrial swelling under ischemic conditions in numerous cell 
types (Birk et al., 2013; Liu et al., 2014; Szeto et al., 2011). By maintaining cristae 
membranes, MTP-131 treated tissues may be better able to sustain ATP synthesis and 
preserve vital ATP-dependent processes (Birk et al., 2013; Szeto et al., 2011). 
Although MTP-131 was known at the outset to selectively partition to the inner 
mitochondria membrane (Zhao et al., 2005), the mechanism by which MTP-131 
protects mitochondrial cristae remained unclear until recently. It is now known, 
however, that MTP-131 has a high affinity for cardiolipin, a unique anionic 
phospholipid (Birk et al., 2013; Szeto, 2014). The conical shape of cardiolipin is 
required to maintain the curvature of cristae, and cardiolipin deficiency results in a 
loss of cristae and reduced mitochondrial respiration (Schlame and Ren, 2006). Since 
cardiolipin contains four unsaturated acyl chains, it is readily peroxidized under 
oxidative conditions, which is consistent with reports that increased cardiolipin 
peroxidation and cardiolipin depletion is present in diabetic hearts (Ferreira et al., 
2013; He and Han, 2014). High glucose has also been postulated to increase 
mitochondrial reactive oxygen species (Brownlee, 2001), and thus, cardiolipin 
peroxidation could have the effect of reducing mitochondrial respiration. Interestingly, 
retinal mitochondria from diabetic mice show elevated superoxide levels and reduced 
glutathione, indicative of mitochondrial oxidative stress (Kanwar et al., 2007). In 
addition to a high reactive oxygen species environment, cardiolipin peroxidation is 
catalyzed by cytochrome c that is tightly bound to cardiolipin, and this [cyt 
c/cardiolipin] complex converts cytochrome c from an electron carrier to a peroxidase 
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that can peroxidize cardiolipin (Kagan et al., 2005; Sinibaldi et al., 2010; Snider et al., 
2013). MTP-131 appears to protect the architecture of mitochondrial cristae by 
reducing mitochondrial oxidative stress and preventing cytochrome c peroxidase 
activity (Birk et al., 2013; Zhao et al., 2004).  
Mitochondrial abnormalities have been documented in insulin-resistant and 
diabetic states in human and animal studies, and it has been proposed that 
mitochondrial dysfunction may be the primary defect in obesity-related insulin 
resistance (Patti and Corvera, 2010). The causal mechanism underlying the 
mitochondrial dysfunction, however, is not fully understood. Although it is often 
assumed that hyperglycemia causes mitochondrial oxidative stress in diabetes, a recent 
study reported lower mitochondrial superoxide and mitochondrial respiratory activity 
in the kidneys of diabetic mice after STZ treatment (Dugan et al., 2013), and suggests 
a loss of functional mitochondria in the latter stages of diabetes (Sharma, 2015) . 
MTP-131 could thus provide a novel approach for treating diabetes, based not on 
mitigating elevated blood glucose, but on enhancing mitochondrial bioenergetics 
through the preservation of mitochondrial cristae, and improved efficiency of the 
electron transfer chain. MTP-131 has displayed an exceptional safety profile in Phase 
1 clinical trials, likely due to its lack of effect on the function of normal mitochondria 
(Siegel et al., 2013). Since the beneficial effects of MTP-131 appear to be independent 
of reducing circulating glucose, the treatment may also be useful in complementing 
therapies aimed at managing the typical symptoms of diabetes. Indeed, based on the 
results reported here, a clinical formulation of topical ophthalmic MTP-131 
(OcuviaTM) has entered a clinical trial for treating diabetic macular edema.  
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MATERIALS AND METHODS 
 
Animal Subjects 
Experimental procedures on animals were conducted in accordance with the 
policies of the Weill Cornell Medical College Institutional Animal Care and Use 
Committee. 151 male C57BL/6 mice obtained from Charles River Laboratories at 3 
weeks of age were group-housed at the Burke Medical Research Institute vivarium. 
They were maintained at 68o-76oF with 30-70% relative humidity, and a photoperiod 
of 12 hour light (6:00 lights on)/12 hour dark (18:00 lights off). 
Disease Modeling  
Mice in control groups were fed a ND (LabDiet Picolab Rodent Diet 5053 (min. 
protein = 20%, crude fat = 4.5%, max. crude fiber = 6.0%) ad libitum over the course 
of the study. Type 1 diabetes is an autoimmune disease that destroys insulin-producing 
pancreatic beta cells, which we modeled by administering the beta cell toxin STZ 
(Sigma S0130) to mice at 8 weeks of age fed a ND (ND+STZ; Arora et al., 2009; 
Gilbert et al., 2011). STZ was prepared in a 7.5 mg/ml sodium citrate buffer (pH 4.5) 
immediately prior to injection. On 5 consecutive days, mice were fasted 4 hours, 
anesthetized with inhaled isoflurane (induction at 2.5–4.5%, maintenance at 1–2% 
evaporated in 1-1.5 L/min O2), before being administered 40 mg/kg intraperitoneal 
STZ.  
Type-2 diabetes is characterized by insulin resistance and the inability of beta cells 
to up-regulate their function. To model this, mice were fed a DD (Bio-Serv Mouse 
Diet F3282; protein = 20.5%, crude fat = 36%, fiber = 0%, carbohydrates = 35.7%) ad 
libitum from 4 weeks of age. To model an accelerated version of type-2 diabetes, 
another group was fed a DD from 4 weeks and administered STZ at 8 weeks of age 
(DD+STZ). 
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MTP-131 Administration 
In one experiment, mice were injected daily with a 1mg/kg solution of MTP-131 
sub-cutaneously (provided by Stealth Peptides Inc, Newton, MA) dissolved in 0.9% 
sterile saline (pH 5.5-6.5), or with saline alone. In another experiment, mice were 
administered MTP-131 as an ophthalmic-formulated solution (OcuviaTM, provided by 
Stealth Peptides, Inc) daily via eye drops (in 0.01M sodium acetate buffer solution (pH 
6.00); 5 ul/eye), or with buffer alone.  
 
Measures of Weight and Blood Glucose 
Mice were weighed, then lightly anesthetized with inhaled isoflurane, and a drop 
of blood was harvested from the tail or submandibular vein. Glucose in the drop was 
measured with a glucometer (AlphaTRAK II Blood Glucose Monitoring System, or 
One Touch Ultra Mini Blood Glucose Monitoring System). A glucose tolerance test 
was also administered periodically; animals were fasted overnight prior to receiving 
D-glucose (1.5 g/kg i.p.). Blood glucose was measured as above prior to and after 10, 
20, 30, 60, and 120 minutes glucose administration. 
 
Tests of Spatial Visual Function 
Spatial thresholds for opto-kinetic tracking of sine-wave gratings were measured 
weekly using a virtual optokinetic system (OptoMotry, CerebralMechanics Inc., 
Medicine Hat, Alberta, Canada; (Prusky et al., 2004). Vertical sine wave gratings 
moving at 12 degrees/second, or gray of the same mean luminance, were projected on 
4 monitors as a virtual cylinder, which surrounded an unrestrained mouse standing on 
a platform at the epicenter. The hub of the cylinder was continually centered between 
the eyes of the mouse to set the SF of the grating at the mouse’s viewing position as it 
shifted its position. Gray was projected while the mouse was moving, but when 
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movement ceased, the gray was replaced with a grating. Grating rotation under these 
circumstances elicited reflexive tracking, which was scored via live video using a 
method of limits procedure with a yes/no criterion. A SF threshold, and contrast 
thresholds at 6 spatial frequencies (0.031, 0.064, 0.092, 0.103, 0.192, 0.272 c/d), were 
generated through each eye separately in a testing session (14 thresholds in ~ 30 
minutes). Michelson contrast sensitivity (CS) was calculated using the average screen 
luminance (maximum –minimum)/(maximum + minimum). Most thresholds were 
generated under photopic lighting conditions (screen luminance= 54 lux), which 
selectively measures cone-based visual function. Rod-based visual function under 
scotopic conditions (1 lux) was also assessed in some animals after dark adaptation 
(>6 hours; Alam et al., 2015). For this, 6.3 ND filters (Lee Filters, USA) were placed 
on the monitors, and infrared lighting and an infrared-sensitive camera (Sony 
Handycam DCR-HC28, Sony, Japan) were used to image the animal.  
 
Ophthalmic Assessments 
A biomicroscope (slit lamp) was used to examine the cornea for clarity, size, 
surface texture, and vascularization, and the iris was inspected for pupil size, 
constriction, reflected luminescence, and synechia. The pupil was then dilated with a 
drop of 0.05% Tropicamide ophthalmic solution, and the lens was scored for cataract 
using a modified version of the Merriam-Focht scoring criterion (MERRIAM and 
FOCHT, 1962; Worgul et al., 1993). An indirect ophthalmoscope was also used to 
inspect the fundus for damage, degeneration, retinal vessel constriction, and optic 
nerve head abnormalities. A modified MacDonald-Shaddock Scoring System was 
used to score the optical quality of eyes at 12 and 32 weeks of age.  
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Statistical Analyses 
Using Graphpad Prism 6 software, two-way, repeated-measures ANOVAs were 
used to make group comparisons. Post-hoc multiple comparisons were performed 
using the Tukey’s or Bonferroni correction methods. Statistical comparisons were 
considered significantly different at p < 0.05.  
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FIGURE LEGENDS 
 
Figure 1. Metabolic dysfunction in mouse models of diabetes. A. Elevated blood 
glucose emerged in ND+STZ, DD and DD+STZ groups by 15 weeks of age (DD = 
215 mg/dL +/- 4.35 (n=7); DD+STZ = 235 mg/dL +/- 2.28 (n=6); ND+STZ = 205 
mg/dL +/- 3.14; (n=12), significantly higher than ND = 161 mg/dL +/- 1.73 (n=7), 
p<0.01) and was sustained out to 32 weeks (DD = 263 mg/dL +/- 1.35 (n=4); 
DD+STZ = 253 mg/dL +/- 2.22 (n=3); ND+STZ = 208 mg/dL +/- 3.64 (n=9), 
significantly higher than ND = 164 mg/dL +/- 2.73 (n=5), p<0.01). B; C. Evidence of 
impaired glucose clearance on a glucose tolerance test was present in each diabetic 
model when measured at 12 (B; GTT1) and 30 weeks (C; GTT2), with DD groups 
being the most impaired. Dashed lines demarcate the upper limit of glucometer 
sensitivity. D. Abnormal weight gain emerged in the diabetic models by 15 weeks 
(DD = 35.2g +/- 3.11, DD+STZ = 41.3g +/- 1.42, ND+STZ = 24.9g +/- 2.31), which 
was significantly different than ND = 29.0g +/- 2.14, p<0.05. +/- SEMs are plotted in 
these and other panels but are often occluded by the data symbols. 
 
Figure 2. Progressive decline of visuomotor function in diabetic models. A. SF 
thresholds under photopic (cone-mediated) conditions did not change in ND mice 
from 12 (0.393 c/d +/- 0.006, (n=7)) to 32 weeks (0.394 c/d +/- 0.001 (n=5), p>0.05). 
Reduced thresholds (average of both eyes) emerged in ND+STZ mice at 12 weeks 
(0.387 c/d +/- 0.003 (n=12), p<0.05), with 17% decline by 32 weeks (0.325 c/d +/- 
0.001 (n=9), p<0.01). Reduced thresholds emerged in DD mice by 9 weeks (0.386 c/d 
+/- 0.002 (n=7), p<0.01), with 29% decline by 32 weeks (0.280 c/d +/- 0.001 (n=4), 
p<0.01), and emerged in DD+STZ mice at 8 weeks (0.327 c/d +/- 0.001 (n=6), 
p<0.01), with 38% decline by 32 weeks (0.244 c/d +/- 0.001c/d (n=3), p<0.01). B. 
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Cone-mediated function was more compromised than rod function in diabetic models 
at 28 weeks. As previously reported (Altimus et al., 2010), rod thresholds (Photopic; 
R) are significantly lower (0.19225 c/d +/- 0.000324) than cone (C) thresholds 
(0.3935c/d +/- 0.0006, p<0.01, n=4) in ND mice. Both rod and cone thresholds were 
reduced from normal in all diabetic models, with the most impairment in cone-
mediated function: ND+STZ (cone: 0.331c/d +/- 0.0005 vs rod: 0.18624c/d +/- 
0.0000342, p<0.01); DD (cone: 0.286c/d +/- 0.00634 vs rod: 0.17268c/d +/- 0.000325, 
p<0.01); DD+STZ (cone: 0.253c/d +/- 0.0000233 vs rod: 0.15813c/d +/- 0.000435, 
p<0.01). C; D; E; F) Progressive decline of CS in diabetic models. C. Normal CS was 
present in ND mice when measured at 4, 12 and 32 weeks. D. CS in ND+STZ mice 
decreased moderately between 12 and 32 weeks at SFs above 0.06 c/d. E. Decreased 
CS was evident at 12 weeks in DD mice and progressed by 32 weeks, particularly at 
the highest SF tested. F. DD+STZ mice displayed the most dysfunction over time, 
such that by 32 weeks, they did not respond at the highest SF tested. 
 
Figure 3. Metabolic dysfunction was not improved by daily systemic treatment with 
MTP-131. Daily MTP-131 treatment is indicated by shading. Dotted lines are traces 
from Fig. 1, depicting the effect of Veh treatment. A. MTP-131 treatment did not 
reduce resting fed blood glucose in any of the experimental groups. B. MTP-131 had 
no effect on glucose clearance at 32 weeks in any experimental group. C. MTP-131 
did not mitigate weight gain in the groups fed a DD.  
 
Figure 4. Reversal of visual dysfunction following daily systemic treatment with 
MTP-131. Daily MTP-131 treatment is indicated by shading. Dotted lines are traces 
from Fig. 1, depicting the effects of Veh treatment. A. Improvement of SF function 
was present within 2 weeks of treatment in ND+STZ mice (MTP-131 vs Veh; 0.382 
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c/d +/- 0.001 (n=7) vs 0.377 c/d +/- 0.006 (n=12)), within 3 weeks in DD mice (MTP-
131 vs Veh: 0.342 c/d +/- 0.001 (n=8) vs. 0.347c/d +/- 0.003 (n=7)), and within 1 
week in DD+STZ mice (MTP-131 vs Veh: 0.340 c/d +/- 0.001 (n=11) vs 0.313c/d +/- 
0.002 (n=6)). Full restoration of function was achieved by 24 weeks in ND+STZ (n=4) 
and DD+STZ (n=8) mice, and by 31 weeks in DD mice (n=5). ND (MTP-131) did not 
differ statistically from ND (Veh) at any age (n=6, p>0.05). B. Cone- and rod-
mediated function was restored by MTP-131 treatment, as measured at 28 weeks of 
age (p>0.05); dotted lines depict the results of Veh-treatment abstracted from Fig. 1. 
C; D; E; F. MTP-131 restored normal CS in each experimental group by 32 weeks. 
 
Figure 5. Daily administration of MTP-131 in eye drops from 12 weeks reversed 
visual decline. A; B. 30 mg/ml MTP-131 did not affect resting blood glucose (A; 
MTP-131 vs Veh, p>0.05 vs a p<0.01 for two way ANOVA on age, interaction and 
treatment condition with ND group after 12 weeks) or body weight (B; (A; MTP-131 
vs Veh, p>0.05 vs a p<0.001 for two way ANOVA on age, interaction and treatment 
condition with ND group). Dotted lines represent control data from ND mice in Fig. 1. 
C. SF function was restored to control values by 20 weeks, 4 weeks earlier than with 
systemic treatment (p>0.05 Eye Drops (Veh) vs Systemic (Veh); p<0.001 for Eye 
Drops (MTP-131) vs ND from 7-19 weeks of age, p<0.05 from 20 weeks of age; Eye 
Drops (MTP-131) vs Systemic (MTP-131) p<0.01 between 17 and 23 weeks of age 
(Fig. 2A)). D. Dose-dependent effect of MTP-131 eye drop treatment; 1 mg/ml had no 
effect (p<0.01 for 30mg/ml group from 13 weeks of age compared to Veh and 1mg/ml 
groups; p<0.01 for 10mg/ml group from 16 weeks of age compared to Veh and 
1mg/ml groups; p<0.001 for 30mg/ml group vs 10mg/ml group from 13 to 29 weeks; 
p>0.05 1mg/ml vs Veh at all points). 
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Figure 6. Daily administration of MTP-131 in eye drops reversed more severe visual 
dysfunction present later in the course of disease. A, B) Treatment with MTP-131 in 
eye drops (30 mg/ml) from 34 weeks (shading) in DD+STZ mice did not change 
markers of metabolic dysfunction (A. Resting blood glucose @52 weeks- MTP-131: 
260 mg/dL +/- 2.64 (n=8) vs Veh: 254 mg/dL +/- 2.11 (n=7), p=0.1363 vs ND: 173 
mg/dL +/- 3.06 (n=4)) or body weight (B. @52 weeks- MTP-131: 56.1g +/- 2.5 vs 
Veh: 56.0g +/- 2.3, p=0.1021 vs ND: 36.5g +/- 3.1). Orange dotted lines represent 
traces from control ND mice in Fig. 1. Orange squares are measures in age-matched 
control mice at 52 weeks. C. Reversal of visual decline was evident after 6 weeks of 
drug treatment, (MTP-131: 0.211 c/d +/- 0.003 vs 0.198 c/d +/- 0.003, p<0.05) and 
recovery to 80% normal (MTP-131: 0.311 c/d +/- 0.003 vs Veh: 0.152 c/d +/- 0.003 vs 
ND: 0.393 c/d +/- 0.001) was evident by 52 weeks. Dotted orange line depicts the 
function of ND mice, and teal line is the effect of MTP-131 eye drop treatment, from 
Fig. 5C. 
 
 
Translational Impact: 
(1) Clinical issue: Current treatments for visual dysfunction in diabetes are focused on 
managing the symptoms of diabetes, such as hyperglycemia, obesity and retinal edema 
in the non-proliferative phase, and on improving clarity of the optical axis, or 
controlling retinal angiogenesis and its consequences in the proliferative stage. These 
treatments have limited efficacy, and able to slow, but not reverse, visual decline. Our 
work describes a novel approach to treating diabetic visual dysfunction based on 
targeting and treating mitochondrial dysfunction with a water-soluble peptide (MTP-
131). 
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(2) Results: We find that progressive decline of spatial visuomotor function emerges 
in mouse models of Type 1 and Type 2 diabetes early in the course of disease; before 
typical symptoms of diabetes, such as hyperglycemia and obesity, are present. Both 
systemic and eye-drop application of MTP-131 early in the course of visual decline, 
are able to prevent further decline and fully reverse dysfunction without normalizing 
aberrant glucose clearance, or elevated blood glucose and weight. Equivalent 
treatment later in disease, after much more severe visual dysfunction is manifest, is 
also able to substantially restore function.  
(3) Implications and future directions: These data indicate that mitochondrial 
dysfunction, which may be detected with spatial measures of visuomotor function, is 
an early and treatable pathophysiology of diabetes that is independent of the other 
symptoms of metabolic dysfunction. They also indicate that improving mitochondrial 
function can treat the visual dysfunction without remediating glucose dysregulation or 
obesity. Thus, mitochondrial-based treatment on its own, or in combination with 
current therapies, may provide a new and more effective approach to treating the 
visual consequences of diabetes at any stage of disease. Since MTP-131 has an 
exceptional human safety profile it has the potential to be rapidly translated into 
clinical trials. 
 
 
 
 
 
 
 
 
   111 
Figure 1 
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Figure 2 
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Figure 3 
 
 
  
   114 
Figure 4 
 
 
  
   115 
Figure 5 
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Figure 6 
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CONCLUSION 
 
 
Almost 100 years have passed since the first treatment for diabetes was 
developed, yet therapeutic options still fail to both fully prevent disease progression 
and mitigate end organ dysfunction in hundreds of millions of people worldwide. For 
decades, research and treatment has focused on the most clinically observable factor: 
blood glucose levels. This approach has proven unsuccessful for numerous reasons, 
the first and foremost being that even strict glycemic control fails to prevent the 
progression of diabetic complications in a large subset of patients (Antonetti, Klein, & 
Gardner, 2012).  
Research focused on hyperglycemia initially described the role of 
mitochondria in the onset and progression of the disease, yet the role was attributed 
incorrectly. The temporal relationship discerned by Brownlee is backwards; 
mitochondrial dysfunction is, first and foremost, a promoter and not a product of 
diabetic tissue damage.  It is true that high glucose concentrations, and high substrate 
load in general, drive mitochondrial dysfunction (Muoio, 2014). Yet mitochondrial 
dysfunction is seen in insulin resistant tissues even before the onset of frank 
hyperglycemia. The reality is the opposite of what Brownlee had proposed: 
mitochondrial dysfunction originates first and results in a crisis of bioenergetics. 
Inadequate energy levels create a circumstance where cells cannot carry out vital 
processes, leading to failure of vision-sustaining tasks (Schütt, Aretz, Auffarth, & 
Kopitz, 2012). Preventing increases in ROS will not fix a problem of decreased ATP, 
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and as more recent research has demonstrated, ROS may in fact be decreased in 
diabetic tissue (Dugan et al., 2013). This view explains why there have been no 
successful antioxidant therapies despite many promising initial studies in cell culture 
and animal models – ROS is not the cause, and thus mitigating it does not solve the 
problem.  
Furthermore, the focus on hyperglycemic damage leads to oversight of the 
complications that may arise from altered insulin signaling. Insulin signaling is tissue 
specific, so while the focus of most diabetes research is on skeletal muscle, the 
insulin-sensitive tissues of the eye play a dissimilar role. During the development of 
diabetes, insulin resistance develops differently in different tissues, requiring a more 
nuanced understanding of insulin action than a simple model based on the liver, fat or 
skeletal muscle (Park et al., 2005). In the eye, where constitutive signaling drives the 
constant uptake of glucose for the metabolically active retina, a decrease in insulin 
sensitivity spells disaster for the vision-sustaining functions depending upon this 
substrate supply (Fort et al., 2011). Even with elevated blood glucose levels, the 
diabetic retina will be starved of glucose, further precipitating the bioenergetic crisis. 
Cell culture studies have additionally complicated the field of diabetes research 
via the Crabtree Effect. When exposed to standard high-glucose media, glycolysis is 
favored over mitochondrial oxidative phosphorylation, leading to a radically different 
bioenergetic profile than would occur in living human tissue (Marroquin, Hynes, 
Dykens, Jamieson, & Will, 2007). Much early research, even investigation of 
mitochondrial involvement in diabetes was done in such systems, despite a complete 
failure of the generalizability of this research. Diabetes is a multifaceted, complex 
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disease of still yet-to-be fully understood origin, which complicates our ability to 
utilize model systems. Many models fail to accurate recapitulate the origin of the 
disease, which can lead promising research away from reality. Gender biases (not 
present in humans) have been demonstrated to complicate mouse model use, as well as 
off-target STZ toxicity (Robinson, Barathi, Chaurasia, Wong, & Kern, 2012) . 
Furthermore, while helpful in elucidating certain information, genetic knockout 
models have a dangerous potential to misinform. Endpoints may look relevant to 
human manifestations of diabetic complications, yet the processes and underlying 
causes are so different that findings must be considered with respect to this often-
forgotten reality. 
Additionally, research on diabetic retinopathy, focused on the human 
manifestations of the disease, has made the mistake of concentrating on what is most 
clinically visible. The visualization techniques that make the vascularization of the 
neuroretina easily observable fail to notice the abnormalities arising in the 
fundamentally critical choroid of the outer retina. It is this blood supply that feeds 80-
90% of the retina’s oxygen and is responsible for so many of the processes necessary 
for vision, yet its less-accessible nature led to a lack of investigation. More recently, 
research has begun to focus on the choroid and RPE, but targeted treatments are just 
beginning.  Novel visualization techniques for animal models and human patients, 
especially the development of outer blood-retinal barrier breakdown assays and 
indocyanine green angiography, will allow for elucidation of early choroidal 
aberrations in the future, potentially generating earlier diagnoses (Mueller et al., 1999; 
Witmer & Kiss, 2013; Xu & Le, 2011). 
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Therapies for diabetic retinopathy have similarly been similarly short sighted. 
VEGF inhibition, the expensive, complicated and marginally successful current gold 
standard for proliferative retinopathy fails to mitigate the underlying basis of the 
disease. VEGF upregulation is driven by hypoxia, and until that condition is mollified 
its increased production will remain. Here, we present a therapeutic basis for breaking 
the feed-forward cycle leading to VEGF secretion, abrogating the underlying basis 
instead of removing one consequent factor. Restoration of adequate bioenergetics 
allows for the endogenous antioxidant, supportive and vision-producing cellular 
functions required to maintain proper retinal function. Our proposed therapy will most 
likely benefit with concomitant pharmacological intervention, but this will require 
future investigation.  
Restoration of the bienergetic capacity of the retina may play a role beyond 
diabetic retinopathy. Age-related macular degeneration in particular poses as a 
potential area necessitating further investigation. The disease shares a similar etiology 
of mitochondrial impairment and diminished bioenergetics (Barot, Gokulgandhi, & 
Mitra, 2011; Feher et al., 2006; Karunadharma, Nordgaard, Olsen, & Ferrington, 
2010). Similar ultrastructural differences are seen in the RPE, as well as early 
neovascular tufts, albeit to a lesser degree (data unpublished). Our lab and 
collaborators have recognized similar visual degeneration of spatial frequency 
threshold, and have compelling preliminary data supporting our therapeutic hypothesis 
with SS-31. 
There is still much work to be done, but the current state of our research has 
generated some exciting results. Restoration of not just biomarkers for visual function, 
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but measurable reversal of diabetes-associated visual dysfunction in a mouse model is 
novel for this field. The focus on preservation of mitochondrial function in order to 
safeguard adequate bioenergetic capacity shifts the focus from blood glucose control 
towards what we believe to be more relevant factors: bioenergetic failure, insulin 
resistance and microvasculopathy.  The recognition of visual dysfunction beginning 
before robust hyperglycemia requires additional research, yet there are other studies 
documenting onset of visual degeneration earlier than is generally noted (Akimov & 
Rentería, 2012; Aung, Kim, Olson, Thule, & Pardue, 2013; Hardy, Lipton, Scase, 
Foster, & Scarpello, 1992; Jackson, Scott, Quillen, Walter, & Gardner, 2012; Kirwin 
et al., 2011).  These factors reframe the contemporary view of diabetic retinopathy as a 
progressive failure with roots earlier than may be commonly recognized. Treatment of 
the disease may be possible via bioenergetic restoration, and without a focus on blood 
glucose control. 
The topical formulation of SS-31 (“Ocuvia”) represents an additional shift in 
treatment paradigm in a number of ways. For the doctor and patient, the treatment may 
represent a lesser cost, greater ease of treatment and reduced risk of complications. 
The side effect profile of SS-31 in phase 1 trials has been excellent, and could provide 
a needed reprieve from a first-line treatment consisting of frequent and invasive 
intravitreal injections. Furthermore, topical SS-31 may provide an excellent form for 
treatment of diabetic retinopathy in developing and low-income countries, where more 
complicated distribution and administration of intravitreal injections, let alone the cost 
of therapy have been prohibitive. 
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 The success or failure of topical SS-31 in humans cannot be guaranteed based 
solely on our animal research. A phase I/II trial currently ongoing will provide data on 
the potential of realization and FDA approval in this indication. Results are scheduled 
for late 2015. 
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